Details of Disease

General Information of Disease (ID: DIS2C5Q8)

• Disease Name: Crohn disease
• Synonyms: Crohn's disease of large bowel; regional enteritis; paediatric Crohn's disease; Crohn disease; granulomatous colitis; pediatric Crohn's disease; Crohn's disease of colon; Crohn's disease
• Disease Class: DD70: Crohn disease
• Definition: A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.
• Disease Hierarchy:
  DISGN23E: Inflammatory bowel disease
  DIS2C5Q8: Crohn disease
• ICD Code:
  ICD-11: ICD-11: DD70
  ICD-10: ICD-10: K50, K50.9
  ICD-9: ICD-9: 555
  Expand ICD-11: 'DD70
  Expand ICD-10: 'K50; 'K50.9
  Expand ICD-9: 555
• Disease Identifiers:
  MONDO ID: MONDO_0005011
  MESH ID: D003424
  UMLS CUI: C0010346
  OMIM ID: 266600
  MedGen ID: 3664
  HPO ID: HP:0100280
  Orphanet ID: 206
  SNOMED CT ID: 34000006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 28 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abatacept	DMSA8RU	Approved	NA	[1]
Adalimumab	DMQMV1B	Approved	Antibody	[2]
Aminosalicylic Acid	DMENSL5	Approved	Small molecular drug	[3]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[4]
Budesonide	DMJIBAW	Approved	Small molecular drug	[5]
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[6]
Citric acid, magnesium oxide, sodium picosulfate	DMMEBWR	Approved	Small molecular drug	[7]
Clofazimine	DMEBOFW	Approved	Small molecular drug	[8]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[9]
Desonide	DMTP2NJ	Approved	Small molecular drug	[10]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[11]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[12]
Infliximab	DMH7OIA	Approved	Antibody	[2]
Mercaptopurine	DMTM2IK	Approved	Small molecular drug	[13]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[14]
Metronidazole	DMTIVEN	Approved	Small molecular drug	[15]
MLN0002	DMP2LZ8	Approved	NA	[16]
Mycophenolic acid	DMRBMAU	Approved	NA	[17]
Naltrexone	DMUL45H	Approved	Small molecular drug	[18]
Natalizumab	DMAK85L	Approved	Monoclonal antibody	[19]
Ozanimod	DMT6AM2	Approved	NA	[20]
Plecanatide	DMKEX7O	Approved	Small molecular drug	[21]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[22]
Prednisone	DM2HG4X	Approved	Small molecular drug	[23]
Ritlecitinib	DMYKNME	Approved	NA	[20]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[24]
Upadacitinib	DM32B5U	Approved	NA	[20]
Vedolizmab	DMV3YMX	Approved	Monoclonal antibody	[17]

This Disease is Treated as An Indication in 60 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-874	DMYHSO2	Phase 3	NA	[25]
AJM-300	DM5K6J4	Phase 3	NA	[26]
Alicaforsen	DMQ509J	Phase 3	Antisense drug	[27]
Alofisel	DMNKI8Y	Phase 3	Cell therapy	[28]
BI 655066	DMBH4FL	Phase 3	Antibody	[20]
Brazikumab	DM4NWPE	Phase 3	Monoclonal antibody	[29]
Entyvio	DMZVI9V	Phase 3	NA	[20]
Etrolizumab	DMR87TR	Phase 3	NA	[20]
GED-0301	DMTUV7L	Phase 3	NA	[20]
GS-5745	DMP8MDW	Phase 3	NA	[20]
MSC-100-IV	DM8EOG6	Phase 3	NA	[20]
PB006	DMVHGLA	Phase 3	Antibody	[30]
Prochymal	DMWTCWM	Phase 3	NA	[31]
Remestemcel-L	DM02MRW	Phase 3	Cell therapy	[32]
RHB-104	DMWAYM7	Phase 3	NA	[20]
Rifaximin DR	DMKTS2M	Phase 3	NA	[20]
SB2	DMS1PFA	Phase 3	NA	[20]
SHP647	DMEWRXA	Phase 3	NA	[20]
SHR0302	DMUL8ZT	Phase 3	Small molecule	[33]
Sivelestat	DM6BZCV	Phase 3	Small molecular drug	[20]
Vercirnon	DM6L5ZQ	Phase 3	Small molecular drug	[34]
ABBV-154	DMVWLET	Phase 2	Antibody drug conjugate	[35]
Alequel	DMH16BZ	Phase 2	NA	[20]
AMG-181	DMODJTX	Phase 2	Antibody	[36]
Anti-IP10	DMVRNAO	Phase 2	Antibody	[37]
APD371	DM3XT5V	Phase 2	NA	[38]
BI 706321	DMSLJZ8	Phase 2	NA	[39]
CC-1088	DMQ874W	Phase 2	Small molecular drug	[40]
EB8018	DM753H8	Phase 2	Small molecular drug	[42]
EGS-21	DMN1SWB	Phase 2	Small molecular drug	[43]
GLPG-0634	DMPHCDL	Phase 2	Small molecular drug	[20]
GSK2330811	DMB0CXT	Phase 2	NA	[44]
MDX-1100	DM0EZWI	Phase 2	Antibody	[45]
MEDI2070	DM8JGIA	Phase 2	NA	[46]
MORF-057	DMS274E	Phase 2	Small molecule	[47]
MT-1303	DMSE9TH	Phase 2	Small molecular drug	[20]
NN8555	DM3IEHP	Phase 2	NA	[20]
OPS-2071	DME8A5R	Phase 2	Small interfering RNA	[48]
PF-04236921	DM826SW	Phase 2	NA	[20]
PRA023	DMUY4VV	Phase 2	Antibody	[49]
SGX203	DMBBR3Y	Phase 2	NA	[20]
STA-5326	DMH4C3M	Phase 2	Small molecular drug	[50]
TEV-48574	DMHWN63	Phase 2	Antibody	[51]
YSIL6	DM0K8U7	Phase 2	NA	[52]
EcoActive	DM5447L	Phase 1/2	NA	[53]
ABBV-323	DM49O6Y	Phase 1	NA	[20]
AMG-139	DMEHOVF	Phase 1	Antibody	[54]
ATR-107	DMBCATZ	Phase 1	Antibody	[55]
AZD7798	DMBE5OK	Phase 1	Antibody	[56]
C326	DMR0S8U	Phase 1	NA	[57]
CCX-025	DMCWVS7	Phase 1	NA	[58]
ChronsVax	DMAPEKO	Phase 1	NA	[20]
CrohnsVax	DMFGYDQ	Phase 1	NA	[59]
ETX201	DMS436I	Phase 1	NA	[20]
ONS-3010	DMVMZ8M	Phase 1	NA	[20]
OSSM-001	DMQ8AD4	Phase 1	Cell therapy	[60]
PF-06480605	DMCX5SX	Phase 1	NA	[61]
SAR252067	DM1OZ7O	Phase 1	NA	[62]
TAK-828	DMW43DL	Phase 1	NA	[20]
VBY-129	DM4YIWK	Phase 1	NA	[20]

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Clazakizumab	DM6ZOUV	Phase 2 Trial	Monoclonal antibody	[41]

This Disease is Treated as An Indication in 188 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alkyl mannoside derivative 1	DMW57UB	Patented	Small molecular drug	[63]
Alkyl mannoside derivative 10	DMHD51F	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 11	DMMNZ2U	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 12	DMX1OZF	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 2	DMNQUKP	Patented	Small molecular drug	[63]
Alkyl mannoside derivative 3	DML2B58	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 4	DMZR71O	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 5	DM04ZJ2	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 6	DMCIV32	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 7	DMBLSH1	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 8	DMZP1JT	Patented	Carbohydrates	[63]
Alkyl mannoside derivative 9	DMV1QUX	Patented	Carbohydrates	[63]
Aryl mannoside derivative 1	DM1TV6F	Patented	Carbohydrates	[63]
Aryl mannoside derivative 10	DM251GL	Patented	Carbohydrates	[63]
Aryl mannoside derivative 11	DMRVIPL	Patented	Carbohydrates	[63]
Aryl mannoside derivative 12	DMOG8XT	Patented	Carbohydrates	[63]
Aryl mannoside derivative 13	DM2W7JE	Patented	Carbohydrates	[63]
Aryl mannoside derivative 14	DMR648Z	Patented	Carbohydrates	[63]
Aryl mannoside derivative 15	DMQS8CF	Patented	Carbohydrates	[63]
Aryl mannoside derivative 16	DMP6QEC	Patented	Carbohydrates	[63]
Aryl mannoside derivative 17	DM0FSPQ	Patented	Carbohydrates	[63]
Aryl mannoside derivative 18	DM0YUBR	Patented	Carbohydrates	[63]
Aryl mannoside derivative 19	DM6K29H	Patented	Carbohydrates	[63]
Aryl mannoside derivative 2	DM4S2U5	Patented	Carbohydrates	[63]
Aryl mannoside derivative 20	DMZ2RV3	Patented	Carbohydrates	[63]
Aryl mannoside derivative 21	DMJBY68	Patented	Carbohydrates	[63]
Aryl mannoside derivative 22	DMJFDNB	Patented	Carbohydrates	[63]
Aryl mannoside derivative 23	DMWUNRV	Patented	Carbohydrates	[63]
Aryl mannoside derivative 3	DMF5XU8	Patented	Carbohydrates	[63]
Aryl mannoside derivative 4	DMO19Y6	Patented	Carbohydrates	[63]
Aryl mannoside derivative 5	DMMC31R	Patented	Carbohydrates	[63]
Aryl mannoside derivative 6	DM5MIEC	Patented	Carbohydrates	[63]
Aryl mannoside derivative 7	DM9YS40	Patented	Carbohydrates	[63]
Aryl mannoside derivative 8	DMK6PFQ	Patented	Carbohydrates	[63]
Aryl mannoside derivative 9	DMNSK7U	Patented	Carbohydrates	[63]
Beta-cyclodextrin conjugate derivative 1	DMZKTHL	Patented	Carbohydrates	[63]
Beta-cyclodextrin conjugate derivative 2	DM9W1FO	Patented	Carbohydrates	[63]
Beta-cyclodextrin conjugate derivative 3	DMQJF4P	Patented	Carbohydrates	[63]
Beta-cyclodextrin conjugate derivative 4	DMO9RE8	Patented	Carbohydrates	[63]
Beta-cyclodextrin conjugate derivative 5	DML2B7G	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 1	DMX6YGS	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 10	DMPF37N	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 11	DMKES0G	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 12	DM5T29W	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 13	DM1Y8OM	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 14	DM4C5QY	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 15	DMKXT7H	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 16	DMP9742	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 17	DMIXV6G	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 18	DMHOPE0	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 19	DME8DQ0	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 2	DMMB60X	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 20	DMNC5S0	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 21	DMGSLHN	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 22	DMYLVB3	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 23	DM2YVGH	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 24	DMF5TB4	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 25	DMRM3E9	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 26	DMYXLCJ	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 27	DMTDPHY	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 28	DMSNMZ2	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 29	DMCLTY3	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 3	DMAITK3	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 30	DMPLAWQ	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 31	DMMPJ3E	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 4	DMVF63N	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 5	DMRS1WG	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 6	DMEWA7U	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 7	DMD7053	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 8	DMWF2VG	Patented	Carbohydrates	[63]
Biaryl mannoside derivative 9	DM1Q7AL	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 1	DMS5UFX	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 10	DMITLPW	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 11	DMZF5XI	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 12	DMU0YST	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 13	DM83LTH	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 14	DMMRTWG	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 15	DM97BIQ	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 16	DMECZVG	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 17	DM7L8T5	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 18	DM2GZ5Y	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 19	DMGA0R6	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 2	DMQB4DR	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 20	DMDIYJ1	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 21	DMTR6BX	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 22	DMQGFKY	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 23	DMC8OVU	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 24	DMLUZ3K	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 25	DMBWQ8L	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 26	DM5Q4T2	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 27	DMWQ6FJ	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 28	DMMOTWK	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 29	DM9H0Q3	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 3	DMOKJEP	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 30	DM81RIY	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 4	DM0VR23	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 5	DMOS03R	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 6	DM93VEB	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 7	DM46NRV	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 8	DMZCWM5	Patented	Carbohydrates	[63]
Biphenyl mannoside derivative 9	DMP52HJ	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 1	DMV6H95	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 2	DMJT1WG	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 3	DMY10T2	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 4	DMRLE65	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 5	DMUG7E9	Patented	Carbohydrates	[63]
C-linked disaccharide biphenyl mannoside derivative 6	DMUILMD	Patented	Carbohydrates	[63]
Mannoside derivative 1	DMIE7U3	Patented	Carbohydrates	[63]
Mannoside derivative 10	DMZYRHN	Patented	Carbohydrates	[63]
Mannoside derivative 11	DM8I051	Patented	Carbohydrates	[63]
Mannoside derivative 12	DM4QUY0	Patented	Carbohydrates	[63]
Mannoside derivative 13	DM0U7P9	Patented	Carbohydrates	[63]
Mannoside derivative 2	DMFEQD2	Patented	Carbohydrates	[63]
Mannoside derivative 3	DMPF2UG	Patented	Carbohydrates	[63]
Mannoside derivative 4	DMZBY73	Patented	Carbohydrates	[63]
Mannoside derivative 5	DMMXNY8	Patented	Carbohydrates	[63]
Mannoside derivative 6	DMCM3NW	Patented	Carbohydrates	[63]
Mannoside derivative 7	DMOUT1F	Patented	Carbohydrates	[63]
Mannoside derivative 8	DMKTJAH	Patented	Carbohydrates	[63]
Mannoside derivative 9	DMIKZXD	Patented	Carbohydrates	[63]
PMID26651364-Compound-105	DMOJVK6	Patented	Carbohydrates	[63]
PMID26651364-Compound-106	DMQZJDF	Patented	Carbohydrates	[63]
PMID26651364-Compound-107	DMMZ1WL	Patented	Carbohydrates	[63]
PMID26651364-Compound-108	DMA7D3K	Patented	Carbohydrates	[63]
PMID26651364-Compound-109	DM01IWV	Patented	Carbohydrates	[63]
PMID26651364-Compound-10a	DMTPBNY	Patented	Carbohydrates	[63]
PMID26651364-Compound-10b	DM16ANH	Patented	Carbohydrates	[63]
PMID26651364-Compound-10c	DMCRNWA	Patented	Carbohydrates	[63]
PMID26651364-Compound-10d	DMGIV3C	Patented	Carbohydrates	[63]
PMID26651364-Compound-110	DMPA3IX	Patented	Carbohydrates	[63]
PMID26651364-Compound-111	DMY9R58	Patented	Carbohydrates	[63]
PMID26651364-Compound-112	DM1LIRP	Patented	Carbohydrates	[63]
PMID26651364-Compound-113	DM6OQKM	Patented	Carbohydrates	[63]
PMID26651364-Compound-114	DM5GHJA	Patented	Carbohydrates	[63]
PMID26651364-Compound-115	DMHIA26	Patented	Carbohydrates	[63]
PMID26651364-Compound-116	DMJ3201	Patented	Carbohydrates	[63]
PMID26651364-Compound-117a	DM6LXHS	Patented	Carbohydrates	[63]
PMID26651364-Compound-117b	DMUQSM1	Patented	Carbohydrates	[63]
PMID26651364-Compound-118	DM6ZRV4	Patented	Carbohydrates	[63]
PMID26651364-Compound-119	DMONAZI	Patented	Carbohydrates	[63]
PMID26651364-Compound-11b	DMGBFK3	Patented	Carbohydrates	[63]
PMID26651364-Compound-11c	DM76WBP	Patented	Carbohydrates	[63]
PMID26651364-Compound-120	DMZTBEQ	Patented	Carbohydrates	[63]
PMID26651364-Compound-121	DM4ZG0Q	Patented	Carbohydrates	[63]
PMID26651364-Compound-122	DMVFTIL	Patented	Carbohydrates	[63]
PMID26651364-Compound-123	DMR0E5W	Patented	Carbohydrates	[63]
PMID26651364-Compound-124	DM6VER5	Patented	Carbohydrates	[63]
PMID26651364-Compound-125	DMINUDB	Patented	Carbohydrates	[63]
PMID26651364-Compound-126a	DMSTKH6	Patented	Carbohydrates	[63]
PMID26651364-Compound-126b	DM2I1QZ	Patented	Carbohydrates	[63]
PMID26651364-Compound-126c	DM80PI1	Patented	Carbohydrates	[63]
PMID26651364-Compound-127	DMEN8RA	Patented	Carbohydrates	[63]
PMID26651364-Compound-128	DM4W0BX	Patented	Carbohydrates	[63]
PMID26651364-Compound-4	DMY0HP1	Patented	Carbohydrates	[63]
PMID26651364-Compound-45	DMLBZGO	Patented	Carbohydrates	[63]
PMID26651364-Compound-46	DMQFDU8	Patented	Carbohydrates	[63]
PMID26651364-Compound-47	DM4S5PB	Patented	Carbohydrates	[63]
PMID26651364-Compound-48	DMHXFGU	Patented	Carbohydrates	[63]
PMID26651364-Compound-49	DMMV5A9	Patented	Carbohydrates	[63]
PMID26651364-Compound-5	DMH7XL3	Patented	Carbohydrates	[63]
PMID26651364-Compound-50	DM6GFYR	Patented	Carbohydrates	[63]
PMID26651364-Compound-5a	DM01GVE	Patented	Carbohydrates	[63]
PMID26651364-Compound-5b	DMLHJ1E	Patented	Carbohydrates	[63]
PMID26651364-Compound-5c	DMDQTA2	Patented	Carbohydrates	[63]
PMID26651364-Compound-5d	DMF6Z5I	Patented	Carbohydrates	[63]
PMID26651364-Compound-5e	DM9TJR5	Patented	Carbohydrates	[63]
PMID26651364-Compound-5f	DMAZIY6	Patented	Carbohydrates	[63]
PMID26651364-Compound-5g	DMSW0HB	Patented	Carbohydrates	[63]
PMID26651364-Compound-6a	DM8HAJ3	Patented	Carbohydrates	[63]
PMID26651364-Compound-6b	DMBINOJ	Patented	Carbohydrates	[63]
PMID26651364-Compound-6c	DMPF86L	Patented	Carbohydrates	[63]
PMID26651364-Compound-6d	DM9J57W	Patented	Carbohydrates	[63]
PMID26651364-Compound-6e	DM4LF0X	Patented	Carbohydrates	[63]
PMID26651364-Compound-7a	DMQMBY9	Patented	Carbohydrates	[63]
PMID26651364-Compound-7b	DM3LCIM	Patented	Carbohydrates	[63]
PMID26651364-Compound-7c	DMGCUJB	Patented	Carbohydrates	[63]
PMID26651364-Compound-7d	DM89VQT	Patented	Carbohydrates	[63]
PMID26651364-Compound-7e	DM2SZ0B	Patented	Carbohydrates	[63]
PMID26651364-Compound-8a	DM1M3WF	Patented	Carbohydrates	[63]
PMID26651364-Compound-8b	DMYVU36	Patented	Carbohydrates	[63]
PMID26651364-Compound-8c	DME7UNT	Patented	Carbohydrates	[63]
PMID26651364-Compound-8d	DMSO2F8	Patented	Carbohydrates	[63]
PMID26651364-Compound-9a	DMAXWPS	Patented	Carbohydrates	[63]
PMID26651364-Compound-9b	DM6HTU0	Patented	Carbohydrates	[63]
PMID26651364-Compound-9c	DM49V8G	Patented	Carbohydrates	[63]
PMID26651364-Compound-9d	DMF0L3E	Patented	Carbohydrates	[63]
PMID26651364-Compound-9e	DM9FIKD	Patented	Carbohydrates	[63]
PMID26651364-Compound-9f	DMF1MV6	Patented	Carbohydrates	[63]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CDP571	DM4HGMX	Discontinued in Phase 3	NA	[64]
ISIS 104838	DMURWPH	Discontinued in Phase 2	Antisense drug	[65]
TNFQb therapeutic vaccines	DMTNB6G	Terminated	Vaccine	[66]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
STP-432	DMINBOS	Investigative	NA	[67]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 296 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADRA1D	TT34BHT	Limited	Genetic Variation	[68]
ALDH5A1	TTJUWVB	Limited	Genetic Variation	[69]
ANTXR2	TTOD34I	Limited	Genetic Variation	[70]
APEH	TTYWEDQ	Limited	Genetic Variation	[71]
ATXN2	TTPQJ7P	Limited	Genetic Variation	[72]
CCL11	TTCF05Y	Limited	Biomarker	[73]
CCND3	TT1JXNR	Limited	Genetic Variation	[72]
CD19	TTW640A	Limited	Biomarker	[74]
CD24	TTCTYNP	Limited	Genetic Variation	[75]
CD28	TTQ13FT	Limited	Biomarker	[76]
CD83	TTT9MRQ	Limited	Altered Expression	[77]
CDC37	TT5SOEU	Limited	Genetic Variation	[72]
COL7A1	TTBCOKN	Limited	Biomarker	[78]
CYP3A4	TTWP7HQ	Limited	Altered Expression	[79]
DPP4	TTDIGC1	Limited	Genetic Variation	[80]
ENTPD1	TTYM8DJ	Limited	Altered Expression	[81]
F13A1	TTXI2RA	Limited	Biomarker	[82]
F9	TTFEZ5Q	Limited	Biomarker	[83]
FCGR3A	TTIFOC0	Limited	Biomarker	[84]
FKBP4	TTHY0FT	Limited	Biomarker	[85]
FOXP3	TT1X3QF	Limited	Biomarker	[86]
GNAO1	TTAXD8Z	Limited	Biomarker	[87]
GRK5	TTTCXO0	Limited	Genetic Variation	[71]
HAMP	TTRV5YJ	Limited	Altered Expression	[88]
HDAC7	TTMUEK1	Limited	Genetic Variation	[70]
HLA-B	TTGS10J	Limited	Genetic Variation	[89]
HLA-DQB2	TTL7VOU	Limited	Biomarker	[87]
HLA-G	TTLKFB3	Limited	Altered Expression	[90]
HNF4A	TT2F3CD	Limited	Biomarker	[91]
IDO1	TTZJYKH	Limited	Altered Expression	[92]
IL13RA2	TTMPZ7V	Limited	Altered Expression	[93]
IL17D	TTC5LTG	Limited	Altered Expression	[94]
IL17F	TT2B6PS	Limited	Biomarker	[95]
IL18	TTRICUF	Limited	Genetic Variation	[96]
IL21	TT9QEJ6	Limited	Biomarker	[97]
IL25	TTVMO5W	Limited	Altered Expression	[98]
IL2RA	TT10Y9E	Limited	Biomarker	[99]
INPP5D	TTTP2Z1	Limited	Biomarker	[100]
IRF1	TT4TU3L	Limited	Altered Expression	[101]
ITGAE	TTH0Z37	Limited	Altered Expression	[102]
JAK1	TT6DM01	Limited	Biomarker	[103]
KCNN1	TT9R6BE	Limited	Biomarker	[104]
KEAP1	TT3Z6Y9	Limited	Genetic Variation	[70]
KLRK1	TTLRN4A	Limited	Biomarker	[105]
KSR1	TTHL1TV	Limited	Genetic Variation	[72]
LAMP1	TTC214J	Limited	Biomarker	[106]
LAMP2	TTULDG7	Limited	Biomarker	[106]
LCT	TTA0OSE	Limited	Genetic Variation	[107]
LTBR	TTFO0PM	Limited	Genetic Variation	[72]
LYZ	TTAOZBW	Limited	Genetic Variation	[108]
MAS1	TTOISYB	Limited	Genetic Variation	[109]
MLH1	TTISG27	Limited	Biomarker	[110]
MTHFR	TTQWOU1	Limited	Genetic Variation	[111]
MUC17	TTVO0JU	Limited	Altered Expression	[112]
MUC5AC	TTEL90S	Limited	Biomarker	[113]
NCF1	TTZ4JC3	Limited	Biomarker	[114]
NFKBIA	TTSHAEB	Limited	Genetic Variation	[115]
NOD1	TTYSRXM	Limited	Biomarker	[116]
NPEPPS	TT371QC	Limited	Genetic Variation	[70]
NR1I2	TT7LCTF	Limited	Altered Expression	[117]
NTF3	TTZHKV9	Limited	Biomarker	[104]
OSMR	TTAH0KM	Limited	Genetic Variation	[72]
P2RX7	TT473XN	Limited	Altered Expression	[118]
PGA5	TTKZ864	Limited	Genetic Variation	[119]
PLA2G1B	TT9V5JH	Limited	Genetic Variation	[108]
PROC	TTZUXYS	Limited	Genetic Variation	[120]
PRTN3	TT5MLC4	Limited	Biomarker	[121]
PSEN2	TTWN3F4	Limited	Altered Expression	[122]
PSMB10	TTPNACM	Limited	Biomarker	[123]
PTPRJ	TTWMKXP	Limited	Altered Expression	[124]
REG4	TTVZEHU	Limited	Altered Expression	[125]
RHOA	TTP2U16	Limited	Genetic Variation	[71]
RIC8B	TT26BHC	Limited	Genetic Variation	[70]
RIPK2	TTCQ2E5	Limited	Biomarker	[126]
RPS6KB1	TTG0U4H	Limited	Genetic Variation	[70]
SH2B3	TT36N7Z	Limited	Genetic Variation	[70]
SH3GL1	TTTYNAM	Limited	Biomarker	[85]
SLC15A1	TT5LF3C	Limited	Biomarker	[127]
SMAD3	TTHQZV7	Limited	Biomarker	[128]
TACR1	TTZPO1L	Limited	Biomarker	[129]
TACR2	TTYO0A3	Limited	Altered Expression	[130]
TLR1	TTW14D0	Limited	Genetic Variation	[131]
TLR8	TT8CWFK	Limited	Genetic Variation	[132]
TNFRSF1B	TT63WSF	Limited	Biomarker	[133]
TNFSF14	TTKVENM	Limited	Altered Expression	[134]
TRB	TT84HCW	Limited	Genetic Variation	[135]
ULK1	TT4D7MJ	Limited	Genetic Variation	[136]
VDAC1	TTAMKGB	Limited	Biomarker	[137]
APOA4	TTNC3WS	Disputed	Altered Expression	[138]
F11R	TT3C8EG	Disputed	Altered Expression	[139]
MAP3K1	TTW8TJI	Disputed	Genetic Variation	[140]
MASP2	TTR01E9	Disputed	Genetic Variation	[141]
NPSR1	TTV1C0Z	Disputed	Genetic Variation	[142]
VIPR1	TTCL30I	Disputed	Altered Expression	[143]
ACO2	TTMTF2P	moderate	Genetic Variation	[144]
ADAM17	TT6AZXG	moderate	Altered Expression	[145]
ADAM30	TTAJDQY	moderate	Genetic Variation	[144]
ANXA1	TTUCK4B	moderate	Altered Expression	[146]
BRD2	TTDP48B	moderate	Genetic Variation	[147]
CCL20	TT2XAZY	moderate	Biomarker	[148]
CCR9	TTIPS8B	moderate	Biomarker	[149]
CLN3	TTORF9W	moderate	Genetic Variation	[150]
CX3CR1	TT2T98G	moderate	Biomarker	[151]
DAG1	TT4X7PG	moderate	Genetic Variation	[152]
DPEP1	TTYUENF	moderate	Biomarker	[153]
EBI3	TTJF68X	moderate	Altered Expression	[154]
ERAP2	TTVGS1C	moderate	Genetic Variation	[72]
GCG	TT6Y4PN	moderate	Biomarker	[155]
GH1	TTT3YKH	moderate	Biomarker	[156]
GPR18	TTSLJAR	moderate	Genetic Variation	[144]
HSP90B1	TTFPKXQ	moderate	Altered Expression	[157]
ICOSLG	TTB9Z8R	moderate	Biomarker	[158]
NLRP1	TTQX29T	moderate	Biomarker	[159]
NT5E	TTK0O6Y	moderate	Biomarker	[160]
SLC10A2	TTPI1M5	moderate	Altered Expression	[161]
SLCO2A1	TTKVTQO	moderate	Biomarker	[162]
TGFB2	TTI0KH6	moderate	Biomarker	[163]
AADAT	TTT3IXG	Strong	Altered Expression	[164]
ACAT1	TTK3C21	Strong	Biomarker	[165]
ADIPOQ	TTXKA7D	Strong	Biomarker	[166]
AGR2	TT9K86S	Strong	Altered Expression	[167]
AHR	TT037IE	Strong	Genetic Variation	[168]
ALPI	TTHYMUV	Strong	Altered Expression	[169]
AOX1	TT3MOS2	Strong	Genetic Variation	[170]
ARRB2	TT8SO2I	Strong	Biomarker	[171]
ATF3	TTCE793	Strong	Biomarker	[172]
ATG2B	TTG6KCU	Strong	Biomarker	[173]
CACNA1E	TTYRP0M	Strong	Biomarker	[174]
CAMP	TTULOB6	Strong	Biomarker	[175]
CBR1	TTVG0SN	Strong	Biomarker	[176]
CCL2	TTNAY0P	Strong	Genetic Variation	[177]
CCL21	TTLZK1U	Strong	Genetic Variation	[178]
CCR1	TTC24WT	Strong	Altered Expression	[179]
CCR6	TTFDB30	Strong	Genetic Variation	[180]
CD160	TTOFEAS	Strong	Biomarker	[95]
CD209	TTBXIM9	Strong	Biomarker	[181]
CD6	TTMF6KC	Strong	Genetic Variation	[70]
CD86	TT53XHB	Strong	Biomarker	[182]
CD96	TT83C4X	Strong	Genetic Variation	[183]
CDH11	TTRGWZC	Strong	Altered Expression	[184]
CDK5R1	TTBYM6V	Strong	Biomarker	[185]
CFB	TTA0P7K	Strong	Biomarker	[186]
CHST15	TTFK7E1	Strong	Biomarker	[187]
CHUK	TT1F8OQ	Strong	Biomarker	[188]
CLEC12A	TT70N8V	Strong	Biomarker	[189]
CSF1	TT0IQER	Strong	Biomarker	[190]
CSF2RA	TT6MP2Z	Strong	Genetic Variation	[191]
CSF2RB	TTPYS82	Strong	Genetic Variation	[192]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[193]
CYP2J2	TTNE1C7	Strong	Altered Expression	[194]
DEFB4A	TTIVY12	Strong	Altered Expression	[195]
DNASE1	TTYWGOJ	Strong	Biomarker	[196]
DNMT3A	TTJUALD	Strong	Genetic Variation	[70]
DPP8	TTJGLZF	Strong	Altered Expression	[197]
EPHB4	TTI4ZX2	Strong	Genetic Variation	[198]
EPHX2	TT7WVHI	Strong	Biomarker	[199]
ERAP1	TT60XFL	Strong	Genetic Variation	[70]
ERN1	TTKIAT3	Strong	Biomarker	[200]
ETS1	TTTGPSD	Strong	Genetic Variation	[70]
FABP5	TTNT2S6	Strong	Biomarker	[201]
FADS2	TTT2VDU	Strong	Genetic Variation	[72]
FAT1	TTGUJYV	Strong	Biomarker	[202]
FCGR1A	TTZK4I3	Strong	Biomarker	[203]
FCGR2A	TTXT21W	Strong	Genetic Variation	[204]
FFAR4	TT08JVB	Strong	Biomarker	[205]
FGF7	TTFY134	Strong	Biomarker	[206]
FN1	TTPJ921	Strong	Biomarker	[207]
FOSL2	TT689IR	Strong	Biomarker	[208]
FPR2	TTOJ1NF	Strong	Biomarker	[209]
FUT3	TTUPAD7	Strong	Genetic Variation	[210]
GART	TTEXB9Z	Strong	Biomarker	[211]
GHR	TTHJWYD	Strong	Altered Expression	[212]
GLP2R	TT1YWO5	Strong	Altered Expression	[213]
GPBAR1	TTSDVTR	Strong	Biomarker	[214]
GPER1	TTDSB34	Strong	Altered Expression	[215]
GPR119	TT7QNVC	Strong	Altered Expression	[216]
GPR3	TTHZVSK	Strong	Altered Expression	[217]
GPR35	TT254XD	Strong	Genetic Variation	[70]
GPR55	TTNET8J	Strong	Biomarker	[218]
GSTA1	TT4P8DE	Strong	Biomarker	[219]
GUCY2C	TTLDPRG	Strong	Genetic Variation	[220]
GUSB	TTHS7CM	Strong	Genetic Variation	[221]
HBB	TTM6HK1	Strong	Biomarker	[222]
HDAC11	TT8K17W	Strong	Biomarker	[223]
HDAC5	TTUELN5	Strong	Altered Expression	[224]
HGFAC	TTD96RW	Strong	Altered Expression	[225]
HPN	TT25MVL	Strong	Biomarker	[226]
HTR7	TTO9X1H	Strong	Biomarker	[182]
IDO2	TTALN9W	Strong	Genetic Variation	[227]
IFNGR2	TT13TL0	Strong	Genetic Variation	[228]
IGF1	TTT6LOU	Strong	Altered Expression	[156]
IL10RB	TTJTRMK	Strong	Genetic Variation	[229]
IL11	TTGUYTR	Strong	Genetic Variation	[230]
IL12A	TTRTK6Y	Strong	Biomarker	[185]
IL12B	TTGW72V	Strong	Genetic Variation	[228]
IL12RB2	TT4SWR8	Strong	Biomarker	[231]
IL13	TT0GVCH	Strong	Biomarker	[232]
IL15RA	TTGN89I	Strong	Altered Expression	[233]
IL16	TTW4R0B	Strong	Altered Expression	[234]
IL18RAP	TTZUJVE	Strong	Genetic Variation	[144]
IL19	TT87RWS	Strong	Genetic Variation	[70]
IL1R1	TTWOTEA	Strong	Biomarker	[235]
IL1RL1	TT4GZA4	Strong	Genetic Variation	[72]
IL21R	TTZO9B0	Strong	Altered Expression	[236]
IL24	TT1EPXZ	Strong	Biomarker	[237]
IL33	TT5MD4P	Strong	Biomarker	[238]
IL37	TTQTX98	Strong	Genetic Variation	[239]
IL5	TTPREZD	Strong	Altered Expression	[240]
IL7	TT8FRMO	Strong	Biomarker	[241]
IRAK1	TTXAJWN	Strong	Biomarker	[242]
IRAK3	TTBPJOK	Strong	Biomarker	[242]
IRF8	TTHUBNK	Strong	Genetic Variation	[243]
ITGAL	TT48WR6	Strong	Genetic Variation	[70]
JAK2	TTRMX3V	Strong	Genetic Variation	[244]
KCNQ2	TTPXI3S	Strong	Biomarker	[245]
KIR2DL2	TTU0P73	Strong	Genetic Variation	[246]
KIR2DL3	TTEX3SI	Strong	Genetic Variation	[246]
KIR2DS1	TTVWAGF	Strong	Genetic Variation	[247]
KIR3DL2	TTQH3N0	Strong	Biomarker	[248]
LANCL2	TTMK3EX	Strong	Biomarker	[86]
LBP	TTVQJLY	Strong	Altered Expression	[249]
LCN2	TTKTLAI	Strong	Altered Expression	[250]
LEP	TTBJEZ5	Strong	Biomarker	[251]
LRRK2	TTK0FEA	Strong	Genetic Variation	[252]
LTA	TTP73TM	Strong	Genetic Variation	[170]
LTF	TTSZDQU	Strong	Biomarker	[253]
LY96	TT8S9AV	Strong	Genetic Variation	[115]
MAP3K14	TT4LIAC	Strong	Genetic Variation	[254]
MAP3K7	TTJQT60	Strong	Altered Expression	[255]
MAP3K8	TTGECUM	Strong	Genetic Variation	[72]
MMP10	TTXLEG7	Strong	Biomarker	[256]
MMP3	TTUZ2L5	Strong	Biomarker	[257]
MST1R	TTBQ3OC	Strong	Genetic Variation	[258]
MYLK2	TTHLGB2	Strong	Biomarker	[259]
NELL1	TT7H4BF	Strong	Biomarker	[260]
NFKB1	TTUIZKC	Strong	Genetic Variation	[261]
NLRP3	TT4EN8X	Strong	Genetic Variation	[262]
NPR1	TTM9IYA	Strong	Biomarker	[263]
NPR3	TTWVLS6	Strong	Biomarker	[220]
NR0B1	TTTK36V	Strong	Biomarker	[264]
NR1H4	TTS4UGC	Strong	Biomarker	[265]
NR5A2	TTAU3SY	Strong	Genetic Variation	[70]
OPRD1	TT27RFC	Strong	Biomarker	[266]
PDCD1LG2	TTW14O3	Strong	Biomarker	[267]
PLA2G2A	TTO8QRU	Strong	Altered Expression	[268]
PLA2G4A	TTT1JVS	Strong	Genetic Variation	[144]
PPARA	TTJ584C	Strong	Biomarker	[265]
PPARG	TTT2SVW	Strong	Altered Expression	[269]
PRKCB	TTYPXQF	Strong	Genetic Variation	[70]
PRKCQ	TT1MS7X	Strong	Genetic Variation	[270]
PSMB9	TTOUSTQ	Strong	Genetic Variation	[271]
PTGER4	TT79WV3	Strong	Biomarker	[91]
PTPN2	TTY8PUS	Strong	Biomarker	[272]
RPGR	TTHBDA9	Strong	Genetic Variation	[273]
RSPO3	TT7HJTF	Strong	Genetic Variation	[72]
SELL	TT2IYXF	Strong	Genetic Variation	[274]
SLC1A5	TTF7WRM	Strong	Altered Expression	[275]
SLC22A1	TTM5Q4V	Strong	Genetic Variation	[276]
SLC23A1	TT6XAGK	Strong	Genetic Variation	[277]
SLCO3A1	TT5CE6L	Strong	Biomarker	[278]
SPN	TTOZAX0	Strong	Biomarker	[279]
ST14	TTPRO7W	Strong	Altered Expression	[280]
SUCNR1	TT4FX9Y	Strong	Altered Expression	[281]
TAP1	TT7JZI8	Strong	Biomarker	[282]
TBX21	TTNF9PH	Strong	Genetic Variation	[228]
TFF1	TTNOJIZ	Strong	Biomarker	[283]
TKT	TT04R7I	Strong	Biomarker	[284]
TLR9	TTSHG0T	Strong	Altered Expression	[285]
TNFAIP3	TT5W0IO	Strong	Biomarker	[286]
TNFRSF14	TTWGTC1	Strong	Genetic Variation	[70]
TNFRSF1A	TTG043C	Strong	Altered Expression	[287]
TNFRSF25	TTDV6BQ	Strong	Biomarker	[288]
TNK2	TTIET93	Strong	Altered Expression	[289]
TSLP	TTHMW3T	Strong	Biomarker	[290]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[291]
VSIR	TT51SK8	Strong	Altered Expression	[292]
ZAP70	TTUMHT8	Strong	Genetic Variation	[293]
ADORA3	TTJFY5U	Definitive	Biomarker	[294]
AOC1	TTM3B5R	Definitive	Genetic Variation	[295]
CCR3	TTD3XFU	Definitive	Altered Expression	[296]
CDH3	TTARMD9	Definitive	Genetic Variation	[243]
DHPS	TTBO2A9	Definitive	Biomarker	[297]
ELAVL1	TTPC9D0	Definitive	Biomarker	[298]
GRB2	TTEYRJ9	Definitive	Biomarker	[299]
IL3RA	TTENHJ0	Definitive	Genetic Variation	[300]
KCNN4	TT7M9I6	Definitive	Genetic Variation	[301]
LPAR6	TTZDAGB	Definitive	Biomarker	[294]
LTB	TTHQ6US	Definitive	Genetic Variation	[302]
MGLL	TTZ963I	Definitive	Biomarker	[303]
P2RY14	TT72OKI	Definitive	Biomarker	[294]
PDX1	TT8SGZK	Definitive	Altered Expression	[304]
PSMB6	TT8EPLT	Definitive	Biomarker	[305]
RORC	TTGV6LY	Definitive	Altered Expression	[306]
SAA1	TTY0DN9	Definitive	Altered Expression	[257]
STK4	TTCPLVN	Definitive	Altered Expression	[307]
TLR6	TTWRI8V	Definitive	Genetic Variation	[308]

This Disease Is Related to 8 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC39A11	DTEOAND	Limited	Genetic Variation	[70]
SLC39A8	DTLPQGT	Limited	Genetic Variation	[309]
SLC9A8	DTNY0C2	Limited	Genetic Variation	[70]
SLC22A23	DTMJK12	moderate	Genetic Variation	[144]
SLC12A2	DTHKL3Q	Strong	Altered Expression	[310]
SLC25A20	DTQOUM4	Strong	Biomarker	[311]
SLC28A3	DT4YL5R	Strong	Altered Expression	[312]
SLC14A2	DT8QC7K	Definitive	Genetic Variation	[257]

This Disease Is Related to 21 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NAT2	DER7TA0	Limited	Genetic Variation	[313]
PARK7	DEPOVCH	Limited	Genetic Variation	[70]
TPMT	DEFQ8VO	Limited	Altered Expression	[314]
UGT1A7	DEZO4N3	Limited	Biomarker	[315]
PON3	DETXQZ1	Disputed	Biomarker	[316]
ACSS2	DEE76VW	moderate	Genetic Variation	[317]
CYP26B1	DEZT8FM	Strong	Genetic Variation	[318]
CYP4F3	DEFCMPI	Strong	Genetic Variation	[319]
EGLN3	DEMQTKH	Strong	Biomarker	[320]
EPHX1	DELB4KP	Strong	Biomarker	[321]
FAAH	DEUM1EX	Strong	Altered Expression	[322]
FADS1	DE05S8C	Strong	Biomarker	[319]
G6PC3	DEE1B8O	Strong	Biomarker	[323]
HPGD	DEHKSC6	Strong	Biomarker	[324]
IPMK	DESA9EX	Strong	Genetic Variation	[325]
KYAT1	DES9MCU	Strong	Altered Expression	[164]
MAT1A	DEQ6NC9	Strong	Biomarker	[165]
NDUFS7	DEIW03B	Strong	Genetic Variation	[326]
P4HA2	DE5EGK0	Strong	Genetic Variation	[327]
XPNPEP1	DE8E6X9	Strong	Biomarker	[328]
CYP4F2	DE3GT9C	Definitive	Genetic Variation	[302]

This Disease Is Related to 409 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACTA2	OTEDLG8E	Limited	Genetic Variation	[70]
ADCY3	OTGOQM6B	Limited	Genetic Variation	[72]
AMT	OTQYEWZQ	Limited	Genetic Variation	[71]
ANKRD55	OT62KZII	Limited	Genetic Variation	[70]
ASAP2	OTGEXULW	Limited	Genetic Variation	[70]
ATN1	OTNZFLKY	Limited	Biomarker	[116]
BACH2	OT17GS18	Limited	Genetic Variation	[329]
BANK1	OTXAAA11	Limited	Genetic Variation	[72]
BCAS3	OTDVAX6B	Limited	Genetic Variation	[71]
BCL3	OT1M5B95	Limited	Biomarker	[242]
C17orf67	OTCL5EE8	Limited	Genetic Variation	[70]
C1orf141	OTASPHL0	Limited	Genetic Variation	[330]
CCL19	OTQ2UJMH	Limited	Biomarker	[331]
CCL25	OTLWJ8CJ	Limited	Altered Expression	[332]
CCNY	OTK1KG5W	Limited	Genetic Variation	[333]
CD226	OT4UG0KB	Limited	Genetic Variation	[70]
CDAN1	OTCVZRG6	Limited	Altered Expression	[334]
CDKAL1	OTA0SGNE	Limited	Genetic Variation	[72]
CDKN2D	OT2TTZPZ	Limited	Biomarker	[83]
CMC1	OTCWYKPI	Limited	Genetic Variation	[70]
CPEB4	OTW1SCZW	Limited	Genetic Variation	[70]
CREM	OTJIJ5AL	Limited	Genetic Variation	[72]
CUL1	OTXPE1UZ	Limited	Genetic Variation	[72]
CUZD1	OTDQJVZ8	Limited	Biomarker	[335]
CXCL6	OTFTCQ4O	Limited	Altered Expression	[336]
DAP	OT5YLL7E	Limited	Genetic Variation	[72]
DDX39A	OT0Z6E1K	Limited	Genetic Variation	[337]
DECR1	OTCDIR6X	Limited	Genetic Variation	[338]
DEFA1	OT5N1B9B	Limited	Biomarker	[339]
ECD	OT3L3PCU	Limited	Altered Expression	[340]
EFNB2	OT0DCUOM	Limited	Altered Expression	[341]
FAM118A	OT6EM97E	Limited	Genetic Variation	[70]
FAM171B	OT4DJHCM	Limited	Genetic Variation	[72]
FAM177A1	OTXTA14N	Limited	Genetic Variation	[70]
FEN1	OT6QGG7O	Limited	Genetic Variation	[72]
FERMT1	OT626PBA	Limited	Genetic Variation	[72]
FIBP	OTI7131S	Limited	Genetic Variation	[70]
FNDC3A	OTUX3S2I	Limited	Genetic Variation	[70]
GAL3ST2	OTZT1PLE	Limited	Genetic Variation	[70]
GLYAT	OT3WWYXD	Limited	Genetic Variation	[70]
GNA12	OT3IRZH3	Limited	Genetic Variation	[70]
GPR65	OTCF5O4G	Limited	Genetic Variation	[72]
HIPK1	OTSEA8RS	Limited	Genetic Variation	[70]
HMMR	OT4M0JTZ	Limited	Biomarker	[342]
HORMAD2	OTL2ENWI	Limited	Genetic Variation	[72]
IFIH1	OTZA2AHA	Limited	Genetic Variation	[70]
IGSF6	OT5TUH02	Limited	Biomarker	[343]
IL18R1	OT83XMPQ	Limited	Genetic Variation	[72]
IL26	OT2WYCW4	Limited	Biomarker	[344]
IL27	OTIS3OF8	Limited	Genetic Variation	[330]
IL6ST	OT1N9C70	Limited	Altered Expression	[345]
IMPG2	OTFPSJ0T	Limited	Genetic Variation	[72]
INAVA	OTGXNB86	Limited	Genetic Variation	[72]
INKA2	OT9RA64U	Limited	Genetic Variation	[330]
ISG20	OTCWRJJW	Limited	Biomarker	[99]
ITGAX	OTOGIMHE	Limited	Biomarker	[346]
ITPA	OTQ47WVR	Limited	Genetic Variation	[347]
JAZF1	OTXTYSYD	Limited	Genetic Variation	[70]
KAT5	OTL7257A	Limited	Altered Expression	[348]
LACC1	OT4SBHI8	Limited	Genetic Variation	[349]
LPP	OT6TU8SE	Limited	Genetic Variation	[72]
LYRM4	OTK6JCKL	Limited	Genetic Variation	[350]
MICA	OTPEIEAR	Limited	Altered Expression	[351]
MUC5B	OTPW6K5C	Limited	Altered Expression	[352]
MYRF	OTKF6AEB	Limited	Genetic Variation	[70]
NDFIP1	OTIORSWF	Limited	Genetic Variation	[72]
NFATC1	OT4TMERS	Limited	Genetic Variation	[70]
NICN1	OTAMQ4EI	Limited	Genetic Variation	[71]
NPL	OTA7P0TO	Limited	Biomarker	[353]
OPTN	OT2UXWH9	Limited	Biomarker	[354]
OSBPL3	OT9G194Y	Limited	Genetic Variation	[71]
PI3	OT47MTC3	Limited	Altered Expression	[355]
PKIG	OTOIWE5G	Limited	Genetic Variation	[70]
PLCL1	OTJL2C79	Limited	Genetic Variation	[72]
PPP2R3C	OT7E6V9B	Limited	Genetic Variation	[70]
PSORS1C1	OT9HK436	Limited	Genetic Variation	[356]
RAVER1	OTMHBTLE	Limited	Genetic Variation	[70]
RDX	OTNSYUN6	Limited	Genetic Variation	[70]
REG1A	OTMHUH1D	Limited	Biomarker	[83]
RFT1	OTW82NET	Limited	Genetic Variation	[72]
RMI2	OTA0HP4S	Limited	Genetic Variation	[72]
RTEL1	OTI3PJCT	Limited	Genetic Variation	[350]
SBNO2	OT1C6J3K	Limited	Genetic Variation	[72]
SCAMP3	OTUNPYCE	Limited	Genetic Variation	[72]
SCYL1	OTQ0IN7P	Limited	Biomarker	[123]
SEMA6A	OTDQ7QAW	Limited	Genetic Variation	[350]
SETD1A	OTVVWRIC	Limited	Genetic Variation	[70]
SFXN1	OTL66767	Limited	Genetic Variation	[357]
SKAP2	OTSF44KP	Limited	Genetic Variation	[70]
SLAMF8	OTATVST8	Limited	Genetic Variation	[72]
STK11	OT1YZSP3	Limited	Genetic Variation	[70]
TCF4	OTB9ASTK	Limited	Altered Expression	[358]
TEX9	OTMYCDCW	Limited	Genetic Variation	[71]
TFF3	OTJJDRTU	Limited	Altered Expression	[359]
TG	OT3ELHIJ	Limited	Biomarker	[360]
THADA	OTYZQX0F	Limited	Genetic Variation	[72]
TMEM258	OTXSDU14	Limited	Genetic Variation	[70]
TNFSF9	OTV9L89D	Limited	Biomarker	[361]
TNIP1	OTRAOTEW	Limited	Genetic Variation	[70]
TRAF3IP2	OTLLZERL	Limited	Biomarker	[362]
TSPAN14	OT29167O	Limited	Genetic Variation	[72]
ACKR2	OTWYY14H	Disputed	Altered Expression	[363]
ARHGDIA	OTEXWJDO	Disputed	Altered Expression	[364]
DNTT	OTFSEF12	Disputed	Genetic Variation	[365]
FCN3	OTPRENLS	Disputed	Genetic Variation	[141]
MUC12	OTYDC13T	Disputed	Biomarker	[366]
MUC13	OTWKS9MF	Disputed	Genetic Variation	[366]
NFKBIL1	OTYFTPS0	Disputed	Genetic Variation	[367]
NLRC4	OTAIA3NA	Disputed	Genetic Variation	[368]
PIGR	OT6GLSUL	Disputed	Altered Expression	[369]
PLA2G10	OTRZ2L5A	Disputed	Altered Expression	[370]
PROSER1	OTV1Y4ON	Disputed	Genetic Variation	[371]
RAD50	OTYMU9G1	Disputed	Genetic Variation	[372]
TNFRSF10C	OTVHOL9B	Disputed	Altered Expression	[373]
ACCS	OTHIHI9D	moderate	Genetic Variation	[317]
ADCY7	OTAWMGP3	moderate	Genetic Variation	[152]
ADGRL2	OTCXD2YR	moderate	Genetic Variation	[152]
ANKRD30A	OTJXYAE5	moderate	Genetic Variation	[152]
ATXN2L	OTP5M3R9	moderate	Genetic Variation	[152]
CAVIN1	OTFO915U	moderate	Genetic Variation	[150]
CD244	OTSMR85N	moderate	Genetic Variation	[150]
CDC42SE2	OT8SG9I1	moderate	Genetic Variation	[144]
CELSR3	OT8P6QNJ	moderate	Genetic Variation	[144]
CHI3L1	OT2Z7VJH	moderate	Biomarker	[374]
CLCA2	OTF191LZ	moderate	Genetic Variation	[375]
CRB1	OTXYUNG0	moderate	Genetic Variation	[152]
CRTC3	OTVIGVUW	moderate	Genetic Variation	[144]
DEFA6	OTDJADMQ	moderate	Biomarker	[376]
DOCK7	OTINNVQV	moderate	Genetic Variation	[144]
DUOX2	OTU14HCN	moderate	Genetic Variation	[377]
ECM1	OT1K65VW	moderate	Biomarker	[378]
ELF1	OTV5LKIA	moderate	Genetic Variation	[271]
FCGR3B	OTSLSPZG	moderate	Biomarker	[84]
FNBP1	OTSJ5KKA	moderate	Genetic Variation	[152]
IL10RA	OTOX3D1D	moderate	Genetic Variation	[379]
INS-IGF2	OTZR74BO	moderate	Genetic Variation	[152]
INTS11	OTOFT19G	moderate	Genetic Variation	[144]
IRF5	OT8SIIAP	moderate	Genetic Variation	[380]
LITAF	OTT5JX1F	moderate	Genetic Variation	[144]
LURAP1L	OTSJ29M5	moderate	Genetic Variation	[152]
MAGI1	OTMV4ASV	moderate	Genetic Variation	[375]
MNAT1	OTXLOYCB	moderate	Genetic Variation	[381]
NKD1	OTY3MO97	moderate	Genetic Variation	[152]
ORMDL3	OTAB7MZF	moderate	Biomarker	[382]
PLA2G15	OT6VJTPA	moderate	Genetic Variation	[317]
PNKD	OT6G9UXN	moderate	Genetic Variation	[144]
RASGRP1	OTX9WN2E	moderate	Genetic Variation	[144]
RGS14	OTYN79AG	moderate	Genetic Variation	[144]
RIT1	OTVNOGOH	moderate	Genetic Variation	[144]
SBSPON	OTBHAW5K	moderate	Genetic Variation	[383]
SGSM3	OTIB1P8A	moderate	Biomarker	[384]
SLAIN2	OTSM5QIO	moderate	Genetic Variation	[144]
SOAT1	OTB4Y5RJ	moderate	Biomarker	[385]
SUOX	OTEJQ9FC	moderate	Genetic Variation	[152]
TAB2	OTPZK76F	moderate	Genetic Variation	[144]
TCTA	OT0AH12O	moderate	Genetic Variation	[350]
TMBIM1	OTE47B57	moderate	Genetic Variation	[144]
TMEM201	OTZBZ4MC	moderate	Biomarker	[386]
TNFSF8	OTDYGDJ3	moderate	Genetic Variation	[271]
ACSBG1	OTM040MW	Strong	Biomarker	[387]
APAF1	OTJWIVY0	Strong	Genetic Variation	[388]
ARF6	OTVV7KJO	Strong	Genetic Variation	[389]
ARHGEF28	OT3F32IU	Strong	Genetic Variation	[390]
ARHGEF6	OTN1ABGL	Strong	Biomarker	[391]
ASAP1	OT4DLRYY	Strong	Biomarker	[339]
ATF2	OTNIZPEA	Strong	Genetic Variation	[392]
ATG16L2	OTJYU0W8	Strong	Biomarker	[393]
ATG5	OT4T5SMS	Strong	Genetic Variation	[70]
ATP6V0A2	OTJBDX0Y	Strong	Biomarker	[394]
AZIN2	OT8OB7CG	Strong	Biomarker	[395]
BAZ1A	OTWHOVZS	Strong	Genetic Variation	[396]
BCKDHA	OT0LHOZB	Strong	Biomarker	[397]
BEST1	OTWHE1ZC	Strong	Biomarker	[398]
BGLAP	OTK1YLWQ	Strong	Biomarker	[399]
BSN	OTZ72VIB	Strong	Genetic Variation	[70]
C4A	OTXMOYXU	Strong	Genetic Variation	[400]
CABIN1	OT4G5CIK	Strong	Biomarker	[401]
CALCOCO2	OTRGX0OV	Strong	Genetic Variation	[402]
CARD10	OT2RPM4I	Strong	Altered Expression	[403]
CARD8	OTXXZYWU	Strong	Genetic Variation	[262]
CARD9	OTJ81AWD	Strong	Biomarker	[382]
CCAR1	OTUXLQZZ	Strong	Biomarker	[404]
CCDC88B	OTEDUI2J	Strong	Altered Expression	[405]
CCL4L2	OTDBSXOU	Strong	Altered Expression	[406]
CCL8	OTCTWYN8	Strong	Altered Expression	[406]
CD1C	OT4XINUJ	Strong	Altered Expression	[407]
CDCA5	OTZLCQ5U	Strong	Biomarker	[185]
CDH13	OTD2CYM5	Strong	Genetic Variation	[72]
CEACAM8	OTLL9WWO	Strong	Altered Expression	[408]
CERS1	OT6EYRM3	Strong	Altered Expression	[409]
CLDN2	OTRF3D6Y	Strong	Genetic Variation	[410]
CLDN5	OTUX60YO	Strong	Altered Expression	[411]
CLDN8	OT7IIWXG	Strong	Biomarker	[412]
CLEC16A	OTLGV5SV	Strong	Genetic Variation	[70]
CLEC4D	OTT7X1UC	Strong	Altered Expression	[413]
COMP	OTS2FPMI	Strong	Altered Expression	[414]
CORIN	OT4SK7DK	Strong	Biomarker	[176]
CORO7	OTG7MEAJ	Strong	Biomarker	[415]
CRNKL1	OTWBQNGU	Strong	Biomarker	[176]
CRX	OTH435SV	Strong	Genetic Variation	[273]
CXCL5	OTZOUPCA	Strong	Altered Expression	[416]
CYLD	OT37FKH0	Strong	Altered Expression	[417]
DEF8	OTS93PPZ	Strong	Altered Expression	[418]
DEFB104A	OTLQZR6K	Strong	Biomarker	[419]
DENND1B	OT3VCNPE	Strong	Genetic Variation	[72]
DLG1	OTCRZYWT	Strong	Genetic Variation	[420]
DMBT1	OTVNU9D9	Strong	Altered Expression	[421]
DOCK11	OTFSTN6A	Strong	Biomarker	[422]
DSC2	OTODVH8K	Strong	Biomarker	[423]
DSG1	OT11HC3A	Strong	Biomarker	[201]
DSG2	OTJPB2TO	Strong	Biomarker	[423]
DSP	OTB2MOP8	Strong	Biomarker	[201]
EIF2A	OTWXELQP	Strong	Altered Expression	[424]
EIF2B5	OTV3R4RB	Strong	Biomarker	[425]
ELAVL3	OTI2VI8B	Strong	Biomarker	[426]
EMSY	OTBQ3KQE	Strong	Genetic Variation	[427]
FCHSD2	OTKXLIJ6	Strong	Genetic Variation	[428]
FCN2	OTTHJBKZ	Strong	Biomarker	[185]
FCRL3	OTIFXFWL	Strong	Biomarker	[429]
FH	OTEQWU6Q	Strong	Altered Expression	[413]
FKBP11	OTY2GC67	Strong	Altered Expression	[430]
FLNB	OTPCOYL6	Strong	Genetic Variation	[431]
FOXP2	OTVX6A59	Strong	Genetic Variation	[432]
FRG1	OTEJ8HSD	Strong	Genetic Variation	[433]
FRG2	OTKIK5HR	Strong	Genetic Variation	[433]
FUT2	OTLXM6WI	Strong	Biomarker	[434]
GADL1	OTJM4A0R	Strong	Biomarker	[395]
GCHFR	OTEOT8GI	Strong	Biomarker	[185]
GCKR	OTSIWXGG	Strong	Genetic Variation	[72]
GDF1	OTZ1VRBH	Strong	Altered Expression	[409]
GNB4	OTC1GPHA	Strong	Biomarker	[435]
GNG11	OTHIXBGW	Strong	Biomarker	[435]
GOT2	OT6XBWN0	Strong	Biomarker	[436]
GP2	OTB6TMGY	Strong	Biomarker	[437]
GPR68	OT1NXSMN	Strong	Biomarker	[438]
GSDMA	OT912R2E	Strong	Altered Expression	[439]
GSDMB	OTWA7P10	Strong	Biomarker	[440]
HAT1	OT307KEN	Strong	Altered Expression	[164]
HEATR3	OTB52FZ4	Strong	Genetic Variation	[441]
HELB	OT769EC5	Strong	Biomarker	[442]
HERC2	OTNQYKOB	Strong	Genetic Variation	[443]
HLA-C	OTV38BUJ	Strong	Biomarker	[248]
HLA-DQB1	OTVVI3UI	Strong	Genetic Variation	[271]
HLA-DRB3	OT5PM9N7	Strong	Genetic Variation	[444]
HLA-DRB5	OTUX5TWM	Strong	Genetic Variation	[325]
HMG20A	OTASVPIF	Strong	Biomarker	[445]
HNRNPD	OT5UO1FA	Strong	Genetic Variation	[446]
HSF2	OTXNJIJ9	Strong	Biomarker	[447]
HSPA6	OTH4S7WB	Strong	Altered Expression	[448]
IFNA10	OTO2FEXF	Strong	Genetic Variation	[449]
IFNA4	OTII5O0G	Strong	Genetic Variation	[449]
IFNGR1	OTCTQBWW	Strong	Genetic Variation	[228]
IL17C	OTKXIVNQ	Strong	Biomarker	[450]
IL18BP	OTW0LRYZ	Strong	Altered Expression	[451]
IL1F10	OTJAASGC	Strong	Biomarker	[452]
IL20RA	OTSIVBVS	Strong	Biomarker	[453]
IL34	OTZ15VVK	Strong	Altered Expression	[454]
IL6R	OTCQL07Z	Strong	Genetic Variation	[455]
IMPACT	OTQ923OB	Strong	Genetic Variation	[456]
INSRR	OT3F75WA	Strong	Biomarker	[457]
IRF6	OTKJ44EV	Strong	Genetic Variation	[72]
ITLN1	OT7ZLJVV	Strong	Genetic Variation	[458]
KAT2A	OTN0W2SW	Strong	Genetic Variation	[223]
KIF21B	OTFXFIU3	Strong	Biomarker	[459]
KPNA1	OTEMVAJ6	Strong	Genetic Variation	[460]
KRT1	OTIOJWA4	Strong	Altered Expression	[461]
KYAT3	OTO4U2QK	Strong	Altered Expression	[164]
LAMB1	OT6J9LJR	Strong	Biomarker	[462]
LDAH	OTXRU9XQ	Strong	Biomarker	[223]
LGALS4	OTKQCG0H	Strong	Altered Expression	[312]
LORICRIN	OTFRPVEO	Strong	Biomarker	[404]
LRG1	OTLD0KWA	Strong	Altered Expression	[463]
LXN	OTZQ2M6Y	Strong	Biomarker	[464]
MACROD2	OTNQCHC6	Strong	Genetic Variation	[432]
MAGI2	OTXDDKZS	Strong	Genetic Variation	[465]
MAP1S	OT5WUD4C	Strong	Biomarker	[466]
MARCHF1	OTI2EYO6	Strong	Biomarker	[467]
MARCHF7	OTG9SF10	Strong	Genetic Variation	[468]
MARCO	OT0NW2Q0	Strong	Biomarker	[469]
MARVELD2	OTKB96L5	Strong	Biomarker	[411]
MDFIC	OTSRYBWZ	Strong	Biomarker	[470]
MED13L	OTSP1W0F	Strong	Biomarker	[471]
MEFV	OTRJ6S6K	Strong	Genetic Variation	[472]
MEGF8	OT5G38CH	Strong	Biomarker	[473]
MEPE	OTXJRUW0	Strong	Biomarker	[474]
MGP	OTZWU3FU	Strong	Biomarker	[475]
MLN	OTBZ5SE5	Strong	Genetic Variation	[428]
MORC4	OTJBEHNE	Strong	Genetic Variation	[410]
MPZ	OTAR2YXH	Strong	Biomarker	[264]
MSC	OTBRPZL5	Strong	Biomarker	[476]
MST1	OTOC4UNG	Strong	Biomarker	[244]
MTFMT	OT1OIVJL	Strong	Biomarker	[470]
MTMR3	OTBIT23O	Strong	Biomarker	[477]
MUC19	OTM06UGV	Strong	Genetic Variation	[244]
MUC2	OT3X4QVX	Strong	Biomarker	[366]
MUC3A	OTI4XUDY	Strong	Altered Expression	[112]
MYDGF	OT9HRPL6	Strong	Altered Expression	[478]
MYLK3	OTC58V2Q	Strong	Biomarker	[259]
MYO9B	OTQ94R5K	Strong	Genetic Variation	[479]
NCR2	OT2H13BX	Strong	Altered Expression	[480]
NEURL1	OT2C4P70	Strong	Biomarker	[481]
NFKBIZ	OTU728KS	Strong	Altered Expression	[482]
NME6	OTJNKOFA	Strong	Altered Expression	[418]
NPC1	OTRIPICX	Strong	Biomarker	[483]
NR2C2	OTDZWVOJ	Strong	Altered Expression	[255]
NSF	OTKRJ2ZT	Strong	Biomarker	[484]
NT5C3A	OT67KZJA	Strong	Biomarker	[185]
NUDT15	OTX8SZOT	Strong	Genetic Variation	[485]
NXF1	OTEFHXG6	Strong	Genetic Variation	[431]
OR10A4	OTYYB8SY	Strong	Biomarker	[486]
ORM2	OTRJGZP8	Strong	Biomarker	[487]
PAFAH1B1	OT9T2TCJ	Strong	Biomarker	[488]
PANX1	OTXPEDOK	Strong	Altered Expression	[489]
PANX2	OTAQ2S8R	Strong	Altered Expression	[490]
PARM1	OTDNK7EX	Strong	Genetic Variation	[491]
PER3	OTVKYVJA	Strong	Genetic Variation	[445]
PGAP3	OTH9A75E	Strong	Altered Expression	[439]
PGLYRP1	OTBTPR2T	Strong	Genetic Variation	[492]
PGLYRP3	OT5C7PRT	Strong	Biomarker	[492]
PGLYRP4	OTI115BR	Strong	Genetic Variation	[492]
PHOX2B	OT3SFR2O	Strong	Genetic Variation	[493]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[435]
PLB1	OTZ6TTYV	Strong	Genetic Variation	[108]
PLCG2	OTGVC9MY	Strong	Genetic Variation	[349]
PMP22	OTXWYWCZ	Strong	Biomarker	[264]
PNN	OT0HXICH	Strong	Biomarker	[481]
POU5F1	OTDHHN7O	Strong	Biomarker	[462]
PPP1R1A	OTGTAGCV	Strong	Biomarker	[494]
PRDM1	OTQLSVBS	Strong	Genetic Variation	[70]
PRDM5	OTU1GB68	Strong	Altered Expression	[495]
PRDX6	OTS8KC8A	Strong	Altered Expression	[496]
PROX1	OT68R6IO	Strong	Altered Expression	[497]
PSMA7	OTPHI6ST	Strong	Altered Expression	[498]
PSTPIP1	OT4PGEAB	Strong	Genetic Variation	[499]
PTPRF	OTH5KF2D	Strong	Biomarker	[500]
PUS10	OTFFJWZX	Strong	Genetic Variation	[72]
RAC2	OTAOHFNH	Strong	Biomarker	[501]
RAP1A	OT5RH6TI	Strong	Biomarker	[330]
RBMXL1	OTMGCWWB	Strong	Altered Expression	[164]
RBX1	OTYA1UIO	Strong	Genetic Variation	[432]
RCL1	OT7O00YX	Strong	Biomarker	[502]
RETN	OTW5Z1NH	Strong	Biomarker	[166]
RNASE2	OT8Z4FNE	Strong	Biomarker	[503]
RNASET2	OTWY64L7	Strong	Biomarker	[504]
RSPO2	OT3HHXU0	Strong	Biomarker	[505]
RTRAF	OTJ6NVMW	Strong	Biomarker	[425]
SAP130	OT01SO0E	Strong	Biomarker	[506]
SEC14L2	OTJST64D	Strong	Genetic Variation	[431]
SEPHS1	OTZ19I59	Strong	Genetic Variation	[507]
SF3B3	OTAC9LZT	Strong	Biomarker	[506]
SNX20	OTNL4B1S	Strong	Genetic Variation	[245]
SUCLA2	OTMZD4PW	Strong	Biomarker	[508]
TAGAP	OTHJNNO2	Strong	Genetic Variation	[509]
TAP2	OTWSYFI7	Strong	Biomarker	[282]
TCF21	OT393IMA	Strong	Biomarker	[415]
TCF7	OT1ID822	Strong	Biomarker	[510]
TCN2	OT41D0L3	Strong	Genetic Variation	[511]
TFF2	OTRXB19X	Strong	Biomarker	[283]
THEMIS	OTXODBXJ	Strong	Biomarker	[512]
THY1	OTVONVTB	Strong	Biomarker	[256]
TLR10	OTQ1KVJO	Strong	Genetic Variation	[513]
TNFAIP6	OT1SLUZH	Strong	Biomarker	[514]
TNFRSF6B	OTKAN9G7	Strong	Genetic Variation	[245]
TOLLIP	OTYEO4NR	Strong	Biomarker	[242]
TRAF3	OT5TQBGV	Strong	Altered Expression	[515]
TRAF4	OTJLRVMC	Strong	Biomarker	[516]
TRAF5	OTSBTLO0	Strong	Altered Expression	[515]
TRAP1	OTNG0L8J	Strong	Biomarker	[517]
TRIM22	OTJBLG5R	Strong	Biomarker	[518]
TTLL5	OTUKOVEM	Strong	Biomarker	[519]
ATG4A	OTDHXAPG	Definitive	Genetic Variation	[520]
CCL7	OTDIS99H	Definitive	Genetic Variation	[521]
CCRL2	OT5PX0RX	Definitive	Biomarker	[522]
CD300LF	OTQWJGSR	Definitive	Genetic Variation	[523]
CD3D	OTRBLP0R	Definitive	Altered Expression	[524]
CLEC10A	OTD8HQT6	Definitive	Biomarker	[303]
CLEC2D	OTVRLKPM	Definitive	Genetic Variation	[303]
CLEC4A	OTNLPK2C	Definitive	Biomarker	[303]
DYM	OTQ670WI	Definitive	Genetic Variation	[525]
ELMO1	OTY2ORXK	Definitive	Genetic Variation	[526]
FBLN5	OTLVNZ8U	Definitive	Biomarker	[527]
FCRL4	OT3DVTRV	Definitive	Biomarker	[257]
FDCSP	OT8KGE9M	Definitive	Altered Expression	[524]
GALNT2	OTZZ5386	Definitive	Altered Expression	[528]
HLA-DRA	OT7KZMP2	Definitive	Genetic Variation	[333]
IER3	OTZJI5FZ	Definitive	Biomarker	[529]
IL17RA	OTVVI8ER	Definitive	Genetic Variation	[530]
ISX	OTULQRWA	Definitive	Biomarker	[231]
KIF3A	OTMUBSSK	Definitive	Biomarker	[531]
LPIN2	OTRRTMXX	Definitive	Biomarker	[532]
MAGT1	OTQSAV5C	Definitive	Altered Expression	[169]
MPRIP	OT5FV5NS	Definitive	Altered Expression	[533]
NAT9	OT4ZKCRS	Definitive	Genetic Variation	[523]
NFIL3	OTQH9HM3	Definitive	Altered Expression	[534]
NLRP11	OTAL4ADW	Definitive	Genetic Variation	[535]
PSMG1	OTZ5I6UM	Definitive	Genetic Variation	[333]
RABGEF1	OTWC3Z3R	Definitive	Biomarker	[536]
RAVER2	OT0MDL7K	Definitive	Genetic Variation	[537]
REEP6	OTY4FPO8	Definitive	Genetic Variation	[538]
REG1B	OTSC2133	Definitive	Biomarker	[257]
RNF138	OTPU0CO4	Definitive	Biomarker	[539]
SHC1	OT1J5IRN	Definitive	Biomarker	[299]
SMAD5	OTQNSVCQ	Definitive	Altered Expression	[540]
STEAP3	OTS9GZK5	Definitive	Altered Expression	[539]
TAC4	OTYWPPM3	Definitive	Altered Expression	[541]
TERF2IP	OT3M5P3G	Definitive	Biomarker	[536]
TLE1	OT50MRZ1	Definitive	Genetic Variation	[528]
TMEM183A	OT1VBS2L	Definitive	Biomarker	[231]
TRAIP	OTMPT9Y2	Definitive	Genetic Variation	[542]

References

• [1] Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57.
• [2] Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
• [3] Aminosalicylic acid FDA Label
• [4] Betamethasone FDA Label
• [5] Budesonide FDA Label
• [6] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [7] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [8] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019500.
• [9] Cortisone acetate FDA Label
• [10] Desonide FDA Label
• [11] Dexamethasone FDA Label
• [12] Hydrocortisone FDA Label
• [13] ClinicalTrials.gov (NCT00846703) The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
• [14] Methylprednisolone FDA Label
• [15] ClinicalTrials.gov (NCT00509639) Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease. U.S. National Institutes of Health.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7437).
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [18] Naltrexone FDA Label
• [19] FDA Approved Drug Products from FDA Official Website.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9-26.
• [22] Prednisolone FDA Label
• [23] Prednisone FDA Label
• [24] Triamcinolone FDA Label
• [25] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019529)
• [27] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [28] ClinicalTrials.gov (NCT03706456) A Phase 3, Multicenter, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Cx601 in the Treatment of Complex Perianal Fistulas in Adult Patients With Crohn's Disease. U.S.National Institutes of Health.
• [29] ClinicalTrials.gov (NCT03961815) An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE). U.S.National Institutes of Health.
• [30] ClinicalTrials.gov (NCT04115488) Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri? in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS). U.S.National Institutes of Health.
• [31] ClinicalTrials.gov (NCT00482092) Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease. U.S. National Institutes of Health.
• [32] ClinicalTrials.gov (NCT01233960) Evaluation of PROCHYMAL for Treatment-refractory Moderate-to-severe Crohn's Disease. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT03677648) A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease. U.S.National Institutes of Health.
• [34] ClinicalTrials.gov (NCT01536418) An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease. U.S. National Institutes of Health.
• [35] ClinicalTrials.gov (NCT05068284) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD. U.S.National Institutes of Health.
• [36] ClinicalTrials.gov (NCT01696396) AMG 181 in Subjects With Moderate to Severe Crohn's Disease. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health.
• [38] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [39] ClinicalTrials.gov (NCT04978493) A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment. U.S.National Institutes of Health.
• [40] ClinicalTrials.gov (NCT00045786) Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes. U.S. National Institutes of Health.
• [41] ClinicalTrials.gov (NCT02015520) Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis. U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT03943446) TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD). U.S. National Institutes of Health.
• [43] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020751)
• [44] ClinicalTrials.gov (NCT04151225) Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease (COSMIS). U.S. National Institutes of Health.
• [45] A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
• [46] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031922)
• [47] ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health.
• [48] ClinicalTrials.gov (NCT03850509) Efficacy and Safety of Oral OPS-2071 in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation. U.S. National Institutes of Health.
• [49] ClinicalTrials.gov (NCT05013905) A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease. U.S.National Institutes of Health.
• [50] A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis. 2006 Jul;12(7):558-65.
• [51] ClinicalTrials.gov (NCT05668013) A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE). U.S.National Institutes of Health.
• [52] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
• [53] ClinicalTrials.gov (NCT03808103) A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia Coli (AIEC) in Patients With Inactive Crohn's Disease (CD). U.S.National Institutes of Health.
• [54] ClinicalTrials.gov (NCT01258205) Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects. U.S. National Institutes of Health.
• [55] Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22.
• [56] ClinicalTrials.gov (NCT05452304) A Phase 1 Randomised, Double-Blind, Placebo-Controlled 3 Part Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7798 Following Single Ascending Dose Administration and Repeat Dose Administration in Healthy Subjects (Including Japanese and Chinese Subjects), and Patients With Crohn's Disease. U.S.National Institutes of Health.
• [57] ClinicalTrials.gov (NCT00353756) Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease. U.S. National Institutes of Health.
• [58] Clinical pipeline report, company report or official report of ChemoCentryx Inc.
• [59] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [60] ClinicalTrials.gov (NCT05407766) A Phase I Safety Study of Allogeneic Bone Marrow Derived MSCs for Refractory Perianal Fistulizing Crohn's Disease. U.S.National Institutes of Health.
• [61] ClinicalTrials.gov (NCT01989143) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605in Healthy Subjects.. U.S. National Institutes of Health.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030237)
• [63] Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
• [64] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003884)
• [65] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013426)
• [66] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034853)
• [67] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [68] LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn's disease patients.JCI Insight. 2017 Mar 23;2(6):e91917. doi: 10.1172/jci.insight.91917.
• [69] The Unsolved Link of Genetic Markers and Crohn's Disease Progression: A North American Cohort Experience.Inflamm Bowel Dis. 2019 Aug 20;25(9):1541-1549. doi: 10.1093/ibd/izz016.
• [70] Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.Nat Genet. 2016 May;48(5):510-8. doi: 10.1038/ng.3528. Epub 2016 Mar 14.
• [71] Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci.Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14747-52. doi: 10.1073/pnas.0706645104. Epub 2007 Sep 5.
• [72] Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760. Epub 2017 Jan 9.
• [73] Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.Gastroenterol Res Pract. 2018 Jul 29;2018:7265812. doi: 10.1155/2018/7265812. eCollection 2018.
• [74] B1a Lymphocytes (CD19+CD5+) Deficiency in Patients with Crohn's Disease and Its Relation with Disease Severity.Dig Dis. 2018;36(3):194-201. doi: 10.1159/000486893. Epub 2018 Feb 8.
• [75] Association between functional CD24 polymorphisms and susceptibility to autoimmune diseases: A meta-analysis.Cell Mol Biol (Noisy-le-grand). 2015 Dec 26;61(8):97-104.
• [76] Decreased CD8+CD28+/CD8+CD28- T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease.Medicine (Baltimore). 2017 Jun;96(26):e7247. doi: 10.1097/MD.0000000000007247.
• [77] Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease.Eur J Immunol. 2003 Jan;33(1):143-51. doi: 10.1002/immu.200390017.
• [78] The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen.J Invest Dermatol. 2002 Jun;118(6):1059-64. doi: 10.1046/j.1523-1747.2002.01772.x.
• [79] Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.Mol Pharm. 2019 Sep 3;16(9):4059-4064. doi: 10.1021/acs.molpharmaceut.9b00459. Epub 2019 Aug 19.
• [80] Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.Ann Pharmacother. 2019 Jul;53(7):697-704. doi: 10.1177/1060028019827852. Epub 2019 Jan 30.
• [81] Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.J Crohns Colitis. 2020 Jul 9;14(6):818-830. doi: 10.1093/ecco-jcc/jjz182.
• [82] Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease.J Gastroenterol Hepatol. 2006 Sep;21(9):1407-11. doi: 10.1111/j.1440-1746.2006.04319.x.
• [83] IL-23 in inflammatory bowel diseases and colon cancer.Cytokine Growth Factor Rev. 2019 Feb;45:1-8. doi: 10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12.
• [84] CD16+ Macrophages Mediate Fibrosis in Inflammatory Bowel Disease.J Crohns Colitis. 2018 Apr 27;12(5):589-599. doi: 10.1093/ecco-jcc/jjx185.
• [85] Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy-A Randomised Prospective Clinical Trial in Children With Crohn's Disease.J Crohns Colitis. 2019 Jul 25;13(7):846-855. doi: 10.1093/ecco-jcc/jjy207.
• [86] The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.Inflamm Bowel Dis. 2020 Mar 4;26(4):643-652. doi: 10.1093/ibd/izz094.
• [87] A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease.Inflamm Bowel Dis. 2003 Jan;9(1):1-9. doi: 10.1097/00054725-200301000-00001.
• [88] Changes in serum hepcidin levels in children with inflammatory bowel disease during anti-inflammatory treatment.J Paediatr Child Health. 2020 Feb;56(2):276-282. doi: 10.1111/jpc.14593. Epub 2019 Aug 14.
• [89] Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.World J Gastroenterol. 2017 Oct 21;23(39):7139-7149. doi: 10.3748/wjg.v23.i39.7139.
• [90] HLA-G is expressed in intestinal samples of ulcerative colitis and Crohn's disease patients and HLA-G5 expression is differentially correlated with TNF and IL-10 cytokine expression.Hum Immunol. 2018 Jun;79(6):477-484. doi: 10.1016/j.humimm.2018.03.006. Epub 2018 Mar 26.
• [91] Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.
• [92] Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.Gastroenterology. 2019 Oct;157(4):1093-1108.e11. doi: 10.1053/j.gastro.2019.07.013. Epub 2019 Jul 17.
• [93] Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.Aliment Pharmacol Ther. 2019 Mar;49(5):572-581. doi: 10.1111/apt.15126. Epub 2019 Jan 20.
• [94] Interleukin 27 is up-regulated in patients with active inflammatory bowel disease.Immunol Res. 2016 Aug;64(4):901-7. doi: 10.1007/s12026-016-8804-z.
• [95] Differential Pathogenic Th17 Profile in Mesenteric Lymph Nodes of Crohn's Disease and Ulcerative Colitis Patients.Front Immunol. 2019 May 28;10:1177. doi: 10.3389/fimmu.2019.01177. eCollection 2019.
• [96] Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells.Int J Mol Med. 2019 Jun;43(6):2291-2302. doi: 10.3892/ijmm.2019.4156. Epub 2019 Apr 4.
• [97] Mucosal Immunity Related to FOXP3(+) Regulatory T Cells, Th17 Cells and Cytokines in Pediatric Inflammatory Bowel Disease.J Korean Med Sci. 2018 Dec 10;33(52):e336. doi: 10.3346/jkms.2018.33.e336. eCollection 2018 Dec 24.
• [98] Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.Arthritis Rheumatol. 2020 Apr;72(4):645-657. doi: 10.1002/art.41169. Epub 2020 Mar 12.
• [99] CD4+ CD25+ FOXP3+ T cell frequency in the peripheral blood is a biomarker that distinguishes intestinal tuberculosis from Crohn's disease.PLoS One. 2018 Feb 28;13(2):e0193433. doi: 10.1371/journal.pone.0193433. eCollection 2018.
• [100] Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice.Gut Microbes. 2019;10(5):578-598. doi: 10.1080/19490976.2018.1560767. Epub 2019 Feb 13.
• [101] Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF- in inflammatory bowel disease.Inflamm Bowel Dis. 2014 Nov;20(11):1950-61. doi: 10.1097/MIB.0000000000000192.
• [102] Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease.Int J Mol Med. 2003 Nov;12(5):715-9.
• [103] Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.Front Pharmacol. 2019 Mar 13;10:212. doi: 10.3389/fphar.2019.00212. eCollection 2019.
• [104] Decreased potassium channel IK1 and its regulator neurotrophin-3 (NT-3) in inflamed human bowel.Neuroreport. 2003 Feb 10;14(2):191-5. doi: 10.1097/00001756-200302100-00006.
• [105] Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.Gut. 2017 Nov;66(11):1918-1925. doi: 10.1136/gutjnl-2016-311824. Epub 2016 Aug 3.
• [106] Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases.Am J Pathol. 2001 Aug;159(2):449-55. doi: 10.1016/S0002-9440(10)61716-6.
• [107] Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis.Gastroenterology. 1999 Oct;117(4):806-13. doi: 10.1016/s0016-5085(99)70338-0.
• [108] Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric -defensins in IBD Patients.J Clin Gastroenterol. 2020 Jul;54(6):e50-e55. doi: 10.1097/MCG.0000000000001146.
• [109] A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews.Am J Hum Genet. 2003 Mar;72(3):509-18. doi: 10.1086/367848. Epub 2003 Feb 7.
• [110] Hyperplastic/serrated polyposis in inflammatory bowel disease: a case series of a previously undescribed entity.Am J Surg Pathol. 2008 Feb;32(2):296-303. doi: 10.1097/PAS.0b013e318150d51b.
• [111] The association of the MTHFR C677T polymorphism with inflammatory bowel diseases in the Israeli Jewish population: An example of genetic heterogeneity.Medicine (Baltimore). 2016 Dec;95(51):e5611. doi: 10.1097/MD.0000000000005611.
• [112] Mucin gene expression in intestinal epithelial cells in Crohn's disease.Gut. 2001 Oct;49(4):544-51. doi: 10.1136/gut.49.4.544.
• [113] Adenocarcinoma within anorectal fistulae: different clinicopathological characteristics between Crohn's disease-associated type and the usual type.Mod Pathol. 2019 Feb;32(2):314-325. doi: 10.1038/s41379-018-0105-8. Epub 2018 Sep 11.
• [114] Chronic granulomatous disease caused by a deficiency in p47(phox) mimicking Crohn's disease.Clin Gastroenterol Hepatol. 2004 Aug;2(8):690-5. doi: 10.1016/s1542-3565(04)00292-7.
• [115] Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.PLoS One. 2014 Jun 27;9(6):e98815. doi: 10.1371/journal.pone.0098815. eCollection 2014.
• [116] NOD1 and NOD2 in inflammation, immunity and disease.Arch Biochem Biophys. 2019 Jul 30;670:69-81. doi: 10.1016/j.abb.2018.12.022. Epub 2018 Dec 19.
• [117] Pregnane X receptor activation constrains mucosal NF-B activity in active inflammatory bowel disease.PLoS One. 2019 Oct 3;14(10):e0221924. doi: 10.1371/journal.pone.0221924. eCollection 2019.
• [118] Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease.Inflamm Bowel Dis. 2014 Mar;20(3):444-57. doi: 10.1097/01.MIB.0000441201.10454.06.
• [119] Lack of an association between polymorphisms of the T-cell receptor alpha-chain and ulcerative colitis.Gastroenterology. 1989 Nov;97(5):1115-20. doi: 10.1016/0016-5085(89)91680-6.
• [120] An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1289-91. doi: 10.1097/00042737-199911000-00018.
• [121] Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease.J Gastroenterol Hepatol. 2018 Mar 7. doi: 10.1111/jgh.14140. Online ahead of print.
• [122] Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract.Gastroenterology. 1991 Feb;100(2):375-9. doi: 10.1016/0016-5085(91)90205-y.
• [123] Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.J Clin Invest. 2006 Dec;116(12):3195-203. doi: 10.1172/JCI28804. Epub 2006 Nov 22.
• [124] Expression of the membrane protein tyrosine phosphatase CD148 in human tissues.Tissue Antigens. 1999 Nov;54(5):485-98. doi: 10.1034/j.1399-0039.1999.540506.x.
• [125] Expression of human REG family genes in inflammatory bowel disease and their molecular mechanism.Immunol Res. 2018 Dec;66(6):800-805. doi: 10.1007/s12026-019-9067-2.
• [126] In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.J Biol Chem. 2014 Oct 24;289(43):29651-64. doi: 10.1074/jbc.M114.591388. Epub 2014 Sep 11.
• [127] Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn's Disease on PEPT1.Biol Pharm Bull. 2017;40(9):1572-1575. doi: 10.1248/bpb.b17-00181.
• [128] Herbs-Partitioned Moxibustion Combined with Acupuncture Inhibits TGF-1-Smad-Snail-Induced Intestinal Epithelial Mesenchymal Transition in Crohn's Disease Model Rats.Evid Based Complement Alternat Med. 2019 May 30;2019:8320250. doi: 10.1155/2019/8320250. eCollection 2019.
• [129] Substance P modulates colitis-associated fibrosis.Am J Pathol. 2010 Nov;177(5):2300-9. doi: 10.2353/ajpath.2010.100314. Epub 2010 Oct 1.
• [130] Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine.Am J Pathol. 2000 Nov;157(5):1511-22. doi: 10.1016/S0002-9440(10)64789-X.
• [131] Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.PLoS One. 2015 Dec 23;10(12):e0145302. doi: 10.1371/journal.pone.0145302. eCollection 2015.
• [132] Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and Behet's diseases.Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S117-22. Epub 2015 Oct 19.
• [133] Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.Gut. 2019 May;68(5):814-828. doi: 10.1136/gutjnl-2017-315671. Epub 2018 May 30.
• [134] The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease.J Immunol. 2005 Jun 15;174(12):8173-82. doi: 10.4049/jimmunol.174.12.8173.
• [135] Regional variation of the alphabeta T cell repertoire in the colon of healthy individuals and patients with Crohn's disease.Hum Immunol. 2002 Jun;63(6):467-80. doi: 10.1016/s0198-8859(02)00378-6.
• [136] A novel Tetra-primer ARMS-PCR based assay for genotyping SNP rs12303764(G/T) of human Unc-51 like kinase 1 gene.Mol Biol Rep. 2017 Feb;44(1):1-4. doi: 10.1007/s11033-016-4087-7. Epub 2016 Oct 25.
• [137] Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.Am J Gastroenterol. 2004 Dec;99(12):2376-84. doi: 10.1111/j.1572-0241.2004.40417.x.
• [138] Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease.Inflamm Bowel Dis. 2007 Apr;13(4):391-7. doi: 10.1002/ibd.20078.
• [139] Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease.Gastroenterology. 2008 Jul;135(1):173-84. doi: 10.1053/j.gastro.2008.04.002. Epub 2008 Apr 11.
• [140] Clinical and molecular characteristics of isolated colonic Crohn's disease.Inflamm Bowel Dis. 2008 Dec;14(12):1667-77. doi: 10.1002/ibd.20517.
• [141] Genetic polymorphisms of mannan binding lectin (MBL), serum levels of MBL, the MBL associated serine protease and H-ficolin in patients with Crohn's disease.Gut. 2007 Feb;56(2):311-2. doi: 10.1136/gut.2006.109504.
• [142] Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease.Gastroenterology. 2007 Sep;133(3):808-17. doi: 10.1053/j.gastro.2007.06.012. Epub 2007 Jun 20.
• [143] Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease.Int J Mol Med. 2007 Aug;20(2):161-7.
• [144] Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.Nat Genet. 2015 Sep;47(9):979-986. doi: 10.1038/ng.3359. Epub 2015 Jul 20.
• [145] Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.Inflamm Bowel Dis. 2018 Jul 12;24(8):1733-1744. doi: 10.1093/ibd/izy126.
• [146] Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease.PLoS One. 2013 Oct 10;8(10):e76969. doi: 10.1371/journal.pone.0076969. eCollection 2013.
• [147] Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population.Sci Rep. 2016 Dec 23;6:39831. doi: 10.1038/srep39831.
• [148] CCL20 Is Negatively Regulated by TGF-1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.J Crohns Colitis. 2017 May 1;11(5):603-609. doi: 10.1093/ecco-jcc/jjw191.
• [149] In-silico guided discovery of novel CCR9 antagonists.J Comput Aided Mol Des. 2018 Apr;32(4):573-582. doi: 10.1007/s10822-018-0113-2. Epub 2018 Mar 26.
• [150] Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.Nat Genet. 2010 Dec;42(12):1118-25. doi: 10.1038/ng.717.
• [151] E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1(+) Leukocyte Trafficking in Mice with Colitis.Mol Pharmacol. 2017 Nov;92(5):502-509. doi: 10.1124/mol.117.108381. Epub 2017 Aug 25.
• [152] Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.
• [153] Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.World J Gastroenterol. 2016 Nov 7;22(41):9117-9126. doi: 10.3748/wjg.v22.i41.9117.
• [154] Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis.Inflamm Bowel Dis. 2005 Jan;11(1):16-23. doi: 10.1097/00054725-200501000-00003.
• [155] Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease.Am J Clin Nutr. 2020 Jan 1;111(1):131-140. doi: 10.1093/ajcn/nqz240.
• [156] Increases in IGF-1 After Anti-TNF- Therapy Are Associated With Bone and Muscle Accrual in Pediatric Crohn Disease.J Clin Endocrinol Metab. 2018 Mar 1;103(3):936-945. doi: 10.1210/jc.2017-01916.
• [157] Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation.Front Immunol. 2017 Dec 11;8:1531. doi: 10.3389/fimmu.2017.01531. eCollection 2017.
• [158] Disease susceptibility genes shared by primary biliary cirrhosis and Crohn's disease in the Japanese population.J Hum Genet. 2015 Sep;60(9):525-31. doi: 10.1038/jhg.2015.59. Epub 2015 Jun 18.
• [159] NLRP1 haplotypes associated with leprosy in Brazilian patients.Infect Genet Evol. 2013 Oct;19:274-9. doi: 10.1016/j.meegid.2013.06.006. Epub 2013 Jun 13.
• [160] CD73 expression in tissue granulomas in distinguishing intestinal tuberculosis from Crohn's disease in a South African cohort.Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1217-1221. doi: 10.1080/00365521.2018.1503326. Epub 2018 Oct 8.
• [161] Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004 Jan;53(1):78-84.
• [162] Distinction between Chronic Enteropathy Associated with the SLCO2A1 Gene and Crohn's Disease.Gut Liver. 2019 Jan 15;13(1):62-66. doi: 10.5009/gnl18261.
• [163] Effect of Oral Nutrition Supplements and TGF-2 on Nutrition and Inflammatory Patterns in Patients With Active Crohn's Disease.Nutr Clin Pract. 2020 Oct;35(5):885-893. doi: 10.1002/ncp.10448. Epub 2019 Dec 15.
• [164] Increased expression of kynurenine aminotransferases mRNA in lymphocytes of patients with inflammatory bowel disease.Therap Adv Gastroenterol. 2019 Oct 19;12:1756284819881304. doi: 10.1177/1756284819881304. eCollection 2019.
• [165] The Adipokine Metrnl Ameliorates Chronic Colitis in Il-10-/- Mice by Attenuating Mesenteric Adipose Tissue Lesions During Spontaneous Colitis.J Crohns Colitis. 2019 Jul 25;13(7):931-941. doi: 10.1093/ecco-jcc/jjz001.
• [166] Hyperadiponectinemia During Infliximab Induction Therapy in Pediatric Crohn Disease.J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):915-919. doi: 10.1097/MPG.0000000000001876.
• [167] Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation.EMBO Mol Med. 2019 Jun;11(6):e10120. doi: 10.15252/emmm.201810120.
• [168] Association of Crohn's Disease with Aryl Hydrocarbon Receptor Gene Polymorphisms in Patients from Southeast China.Immunol Invest. 2019 Nov;48(8):809-821. doi: 10.1080/08820139.2019.1569677. Epub 2019 Aug 13.
• [169] Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease.World J Gastroenterol. 2012 Jul 7;18(25):3254-9. doi: 10.3748/wjg.v18.i25.3254.
• [170] Polymorphisms of the TNF Gene and Three Susceptibility Loci Are Associated with Crohn's Disease and Perianal Fistula Crohn's Disease: A Study among the Han Population from South China.Med Sci Monit. 2019 Dec 17;25:9637-9650. doi: 10.12659/MSM.917244.
• [171] -Arrestin2 encourages inflammation-induced epithelial apoptosis through ER stress/PUMA in colitis.Mucosal Immunol. 2015 May;8(3):683-95. doi: 10.1038/mi.2014.104. Epub 2014 Nov 5.
• [172] Activating transcription factor 3 promotes intestinal epithelial cell apoptosis in Crohn's disease.Pathol Res Pract. 2018 Jun;214(6):862-870. doi: 10.1016/j.prp.2018.04.013. Epub 2018 Apr 22.
• [173] MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase Inflammatory Responses in Crohn's Disease.Inflamm Bowel Dis. 2018 Mar 19;24(4):781-791. doi: 10.1093/ibd/izx075.
• [174] DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease.Eur J Gastroenterol Hepatol. 2018 Apr;30(4):447-455. doi: 10.1097/MEG.0000000000001055.
• [175] Disorder-to-helix conformational conversion of the human immunomodulatory peptide LL-37 induced by antiinflammatory drugs, food dyes and some metabolites.Int J Biol Macromol. 2019 May 15;129:50-60. doi: 10.1016/j.ijbiomac.2019.01.209. Epub 2019 Feb 1.
• [176] Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2013 Mar;37(5):546-54. doi: 10.1111/apt.12218. Epub 2013 Jan 24.
• [177] Association of MCP-1-2518A/G polymorphism with susceptibility to autoimmune diseases: a meta-analysis.Clin Rheumatol. 2016 May;35(5):1169-79. doi: 10.1007/s10067-015-3060-5. Epub 2015 Aug 29.
• [178] Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes.Br J Nutr. 2007 Aug;98(2):345-50. doi: 10.1017/S0007114507705020. Epub 2007 Mar 29.
• [179] Mucosal CCR1 gene expression as a marker of molecular activity in Crohn's disease: preliminary data.Rom J Morphol Embryol. 2017;58(4):1263-1268.
• [180] Mutation-Induced Functional Alterations of CCR6.J Pharmacol Exp Ther. 2017 Jan;360(1):106-116. doi: 10.1124/jpet.116.237669. Epub 2016 Oct 27.
• [181] CD209 in inflammatory bowel disease: a case-control study in the Spanish population.BMC Med Genet. 2007 Dec 10;8:75. doi: 10.1186/1471-2350-8-75.
• [182] Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract.Inflamm Bowel Dis. 2014 Sep;20(9):1516-29. doi: 10.1097/MIB.0000000000000150.
• [183] Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.Pharmacogenomics J. 2019 Dec;19(6):547-555. doi: 10.1038/s41397-019-0090-4. Epub 2019 May 2.
• [184] Cadherin-11 Is a Regulator of Intestinal Fibrosis.J Crohns Colitis. 2020 Mar 13;14(3):406-417. doi: 10.1093/ecco-jcc/jjz147.
• [185] Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis.Vet Microbiol. 2000 Dec 20;77(3-4):497-504. doi: 10.1016/s0378-1135(00)00334-5.
• [186] Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease.Inflamm Bowel Dis. 2014 Jun;20(6):995-1003. doi: 10.1097/MIB.0000000000000035.
• [187] Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.J Crohns Colitis. 2017 Feb;11(2):221-228. doi: 10.1093/ecco-jcc/jjw143. Epub 2016 Aug 1.
• [188] A TPL2 (MAP3K8) disease-risk polymorphism increases TPL2 expression thereby leading to increased pattern recognition receptor-initiated caspase-1 and caspase-8 activation, signalling and cytokine secretion.Gut. 2016 Nov;65(11):1799-1811. doi: 10.1136/gutjnl-2014-308922. Epub 2015 Jul 27.
• [189] Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy.Cell Rep. 2015 Jun 30;11(12):1905-18. doi: 10.1016/j.celrep.2015.05.045. Epub 2015 Jun 18.
• [190] The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.PLoS One. 2019 Nov 11;14(11):e0223918. doi: 10.1371/journal.pone.0223918. eCollection 2019.
• [191] Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn's Disease.Inflamm Bowel Dis. 2019 Feb 21;25(3):547-560. doi: 10.1093/ibd/izy265.
• [192] A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF.Gastroenterology. 2016 Oct;151(4):710-723.e2. doi: 10.1053/j.gastro.2016.06.045. Epub 2016 Jul 1.
• [193] Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases.Inflamm Bowel Dis. 2014 May;20(5):783-9. doi: 10.1097/MIB.0000000000000014.
• [194] Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?.PLoS One. 2013 Sep 13;8(9):e75107. doi: 10.1371/journal.pone.0075107. eCollection 2013.
• [195] Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue.Sci Rep. 2018 Aug 27;8(1):12886. doi: 10.1038/s41598-018-31125-x.
• [196] Incorporating functional annotation information in prioritizing disease associated SNPs from genome wide association studies.Sci China Life Sci. 2014 Nov;57(11):1072-9. doi: 10.1007/s11427-014-4754-7. Epub 2014 Oct 17.
• [197] The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.J Cell Biochem. 2018 Aug;119(8):6743-6755. doi: 10.1002/jcb.26867. Epub 2018 Apr 25.
• [198] Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.Hum Mol Genet. 2019 Oct 15;28(20):3498-3513. doi: 10.1093/hmg/ddz145.
• [199] Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.PLoS One. 2019 Apr 19;14(4):e0215033. doi: 10.1371/journal.pone.0215033. eCollection 2019.
• [200] Defective ATG16L1-mediated removal of IRE1 drives Crohn's disease-like ileitis.J Exp Med. 2017 Feb;214(2):401-422. doi: 10.1084/jem.20160791. Epub 2017 Jan 12.
• [201] Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease.Mol Cell Proteomics. 2017 Jul;16(7):1244-1257. doi: 10.1074/mcp.M116.066506. Epub 2017 May 10.
• [202] Thickness of Subcutaneous Fat Is a Predictive Factor of Incisional Surgical Site Infection in Crohn's Disease Surgery: A Retrospective Study.Gastroenterol Res Pract. 2018 Jul 22;2018:1546075. doi: 10.1155/2018/1546075. eCollection 2018.
• [203] Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.Inflamm Bowel Dis. 2017 Dec 19;24(1):198-208. doi: 10.1093/ibd/izx022.
• [204] Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.Pharmacogenomics. 2016 Aug;17(13):1465-77. doi: 10.2217/pgs.16.27. Epub 2016 Aug 4.
• [205] GPR120, a potential therapeutic target for experimental colitis in IL-10 deficient mice.Oncotarget. 2017 Jan 31;8(5):8397-8405. doi: 10.18632/oncotarget.14210.
• [206] Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts.Am J Pathol. 1997 Nov;151(5):1469-76.
• [207] Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease.Gastroenterology. 2010 Jan;138(1):285-93. doi: 10.1053/j.gastro.2009.09.003. Epub 2009 Sep 12.
• [208] Human retinoic acid-regulated CD161(+) regulatory T cells support wound repair in intestinal mucosa.Nat Immunol. 2018 Dec;19(12):1403-1414. doi: 10.1038/s41590-018-0230-z. Epub 2018 Nov 5.
• [209] Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G487-97. doi: 10.1152/ajpgi.00042.2011. Epub 2011 Jun 9.
• [210] Associations of FUT2 and FUT3 gene polymorphisms with Crohn's disease in Chinese patients.J Gastroenterol Hepatol. 2014 Oct;29(10):1778-85. doi: 10.1111/jgh.12599.
• [211] GART mediates the renewal of intestinal epithelial barrier via p38/p53/PUMA cascade in colitis.Apoptosis. 2016 Dec;21(12):1386-1397. doi: 10.1007/s10495-016-1301-y.
• [212] Growth Hormone Receptor Gene Expression Increase Reflects Nutritional Status Improvement in Patients Affected by Crohn's Disease.Front Pediatr. 2018 Nov 12;6:338. doi: 10.3389/fped.2018.00338. eCollection 2018.
• [213] GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn's disease.Mol Cell Endocrinol. 2012 Nov 25;364(1-2):46-53. doi: 10.1016/j.mce.2012.08.008. Epub 2012 Aug 19.
• [214] TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease.Immunology. 2013 May;139(1):19-29. doi: 10.1111/imm.12045.
• [215] Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors.Int J Mol Sci. 2019 Jun 28;20(13):3175. doi: 10.3390/ijms20133175.
• [216] Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.Sci Rep. 2019 Feb 20;9(1):2358. doi: 10.1038/s41598-019-38865-4.
• [217] The CARD8 p.C10X mutation associates with a low anti-glycans antibody response in patients with Crohn's disease.BMC Med Genet. 2013 Mar 18;14:35. doi: 10.1186/1471-2350-14-35.
• [218] G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):711-715. doi: 10.1080/00365521.2017.1298834. Epub 2017 Mar 8.
• [219] Comprehensive bioinformatics analyses of Crohn's disease.Mol Med Rep. 2017 Apr;15(4):2267-2272. doi: 10.3892/mmr.2017.6250. Epub 2017 Feb 28.
• [220] Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease.Inflamm Bowel Dis. 2017 Oct;23(10):1752-1761. doi: 10.1097/MIB.0000000000001264.
• [221] Unique -Glucuronidase Locus in Gut Microbiomes of Crohn's Disease Patients and Unaffected First-Degree Relatives.PLoS One. 2016 Jan 29;11(1):e0148291. doi: 10.1371/journal.pone.0148291. eCollection 2016.
• [222] Vitamin D Status Is Associated with Hepcidin and Hemoglobin Concentrations in Children with Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Sep;23(9):1650-1658. doi: 10.1097/MIB.0000000000001178.
• [223] Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.Gastroenterology. 2015 Nov;149(6):1575-1586. doi: 10.1053/j.gastro.2015.07.065. Epub 2015 Aug 14.
• [224] Epigenetic modification of intestinal smooth muscle cell phenotype during proliferation.Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C722-C733. doi: 10.1152/ajpcell.00216.2018. Epub 2018 Aug 15.
• [225] Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn's Disease.PLoS One. 2017 Jan 23;12(1):e0170506. doi: 10.1371/journal.pone.0170506. eCollection 2017.
• [226] An international study of the quality of life of adult patients treated with home parenteral nutrition.Clin Nutr. 2019 Aug;38(4):1788-1796. doi: 10.1016/j.clnu.2018.07.024. Epub 2018 Aug 6.
• [227] IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.PLoS One. 2014 Dec 26;9(12):e115848. doi: 10.1371/journal.pone.0115848. eCollection 2014.
• [228] Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Pharmacogenomics J. 2018 Jan;18(1):87-97. doi: 10.1038/tpj.2016.84. Epub 2017 Jan 31.
• [229] IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013 Jan;19(1):115-23. doi: 10.1002/ibd.22974.
• [230] A polymorphism in the IL11 gene is associated with ulcerative colitis.Genes Immun. 2002 Dec;3(8):494-6. doi: 10.1038/sj.gene.6363897.
• [231] SNP-SNP interactions discovered by logic regression explain Crohn's disease genetics.PLoS One. 2012;7(10):e43035. doi: 10.1371/journal.pone.0043035. Epub 2012 Oct 12.
• [232] The role of interleukin-13 in chronic inflammatory intestinal disorders.Autoimmun Rev. 2019 May;18(5):549-555. doi: 10.1016/j.autrev.2019.03.012. Epub 2019 Mar 4.
• [233] Interleukin-15 receptor expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.Immunology. 2013 Jan;138(1):47-56. doi: 10.1111/imm.12014.
• [234] The -295T-to-C promoter polymorphism of the IL-16 gene is associated with Crohn's disease.Clin Immunol. 2003 Mar;106(3):197-200. doi: 10.1016/s1521-6616(03)00021-4.
• [235] Role of IL-1ra and Granzyme B as biomarkers in active Crohn's disease patients.Biomarkers. 2018 Mar;23(2):161-166. doi: 10.1080/1354750X.2017.1387933. Epub 2017 Oct 16.
• [236] Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease.Gastroenterol Res Pract. 2018 Apr 10;2018:5962624. doi: 10.1155/2018/5962624. eCollection 2018.
• [237] Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study.Clin Exp Immunol. 2014 Jul;177(1):64-75. doi: 10.1111/cei.12285.
• [238] Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis.Mucosal Immunol. 2019 May;12(3):632-643. doi: 10.1038/s41385-019-0138-4. Epub 2019 Feb 11.
• [239] Suleiman AA, Khatri A, Minocha M, Othman AA: Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Clin Pharmacokinet. 2019 Mar;58(3):375-387. doi: 10.1007/s40262-018-0704-z.
• [240] Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.Gastroenterology. 2017 May;152(6):1345-1357.e7. doi: 10.1053/j.gastro.2017.01.016. Epub 2017 Jan 26.
• [241] IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.J Clin Invest. 2019 Apr 2;129(5):1910-1925. doi: 10.1172/JCI121668. eCollection 2019 Apr 2.
• [242] Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?.Clin Exp Immunol. 2016 Mar;183(3):358-68. doi: 10.1111/cei.12732. Epub 2015 Nov 26.
• [243] Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease.Am J Hum Genet. 2011 Dec 9;89(6):798-805. doi: 10.1016/j.ajhg.2011.11.006.
• [244] A novel susceptibility locus in MST1 and gene-gene interaction network for Crohn's disease in the Chinese population.J Cell Mol Med. 2018 Apr;22(4):2368-2377. doi: 10.1111/jcmm.13530. Epub 2018 Feb 14.
• [245] Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease.Gastroenterology. 2017 Jan;152(1):206-217.e2. doi: 10.1053/j.gastro.2016.09.032. Epub 2016 Sep 28.
• [246] Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn's disease.Hum Immunol. 2016 Jan;77(1):104-109. doi: 10.1016/j.humimm.2015.10.020. Epub 2015 Nov 2.
• [247] Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies.PLoS One. 2019 Jun 13;14(6):e0217767. doi: 10.1371/journal.pone.0217767. eCollection 2019.
• [248] HLA-C*01 is a Risk Factor for Crohn's Disease.Inflamm Bowel Dis. 2016 Apr;22(4):796-806. doi: 10.1097/MIB.0000000000000693.
• [249] Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.Inflamm Bowel Dis. 2011 Mar;17(3):767-77. doi: 10.1002/ibd.21402. Epub 2010 Sep 23.
• [250] Ulcer-associated cell lineage expresses genes involved in regeneration and is hallmarked by high neutrophil gelatinase-associated lipocalin (NGAL) levels.J Pathol. 2019 Jul;248(3):316-325. doi: 10.1002/path.5258. Epub 2019 Mar 19.
• [251] Joint analysis of individual-level and summary-level GWAS data by leveraging pleiotropy.Bioinformatics. 2019 May 15;35(10):1729-1736. doi: 10.1093/bioinformatics/bty870.
• [252] Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner.Sci Transl Med. 2019 Sep 25;11(511):eaas9292. doi: 10.1126/scitranslmed.aas9292.
• [253] Crohn's disease IRGM risk alleles are associated with altered gene expression in human tissues.Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G95-G105. doi: 10.1152/ajpgi.00196.2018. Epub 2018 Oct 18.
• [254] Associations between functional polymorphisms in the NFB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Pharmacogenomics J. 2014 Dec;14(6):526-34. doi: 10.1038/tpj.2014.19. Epub 2014 Apr 29.
• [255] TAK1 is a key modulator of the profibrogenic phenotype of human ileal myofibroblasts in Crohn's disease.Am J Physiol Gastrointest Liver Physiol. 2015 Sep 15;309(6):G443-54. doi: 10.1152/ajpgi.00400.2014. Epub 2015 Jul 16.
• [256] Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses.Int Immunol. 2020 Jan 9;32(1):57-68. doi: 10.1093/intimm/dxz060.
• [257] Characterization of intestinal gene expression profiles in Crohn's disease by genome-wide microarray analysis.Inflamm Bowel Dis. 2010 Oct;16(10):1717-28. doi: 10.1002/ibd.21263.
• [258] Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility.Genes Immun. 2009 Oct;10(7):631-5. doi: 10.1038/gene.2009.56. Epub 2009 Aug 6.
• [259] Herbs-partitioned moxibustion improves intestinal epithelial tight junctions by upregulating A20 expression in a mouse model of Crohn's disease.Biomed Pharmacother. 2019 Oct;118:109149. doi: 10.1016/j.biopha.2019.109149. Epub 2019 Jul 12.
• [260] NELL1, NCF4, and FAM92B genes are not major susceptibility genes for Crohn's disease in Canadian children and young adults.Inflamm Bowel Dis. 2012 Mar;18(3):529-35. doi: 10.1002/ibd.21708. Epub 2011 Apr 6.
• [261] High-throughput characterization of genetic effects on DNA-protein binding and gene transcription.Genome Res. 2018 Nov;28(11):1701-1708. doi: 10.1101/gr.237354.118. Epub 2018 Sep 25.
• [262] Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease. J Clin Invest. 2018 May 1;128(5):1793-1806. doi: 10.1172/JCI98642. Epub 2018 Mar 26.
• [263] Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).Scand J Gastroenterol. 2017 Feb;52(2):216-221. doi: 10.1080/00365521.2016.1246605. Epub 2016 Oct 31.
• [264] Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease.Pharmacol Rep. 2017 Jun;69(3):386-392. doi: 10.1016/j.pharep.2017.01.003. Epub 2017 Jan 12.
• [265] Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation.PLoS One. 2011;6(7):e22978. doi: 10.1371/journal.pone.0022978. Epub 2011 Jul 29.
• [266] Vitamin D metabolites are lower with active Crohn's disease and spontaneously recover with development of remission.Therap Adv Gastroenterol. 2019 Jul 26;12:1756284819865144. doi: 10.1177/1756284819865144. eCollection 2019.
• [267] Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells.Clin Transl Immunology. 2019 Jul 25;8(7):e01071. doi: 10.1002/cti2.1071. eCollection 2019.
• [268] Expression of group XIIA phospholipase A2 in human digestive organs.APMIS. 2014 Dec;122(12):1171-7. doi: 10.1111/apm.12280. Epub 2014 May 26.
• [269] Dietary n? polyunsaturated fatty acids ameliorate Crohn's disease in rats by modulating the expression of PPAR?NFAT.Mol Med Rep. 2017 Dec;16(6):8315-8322. doi: 10.3892/mmr.2017.7673. Epub 2017 Sep 29.
• [270] Missense mutation in PRKCQ is associated with Crohn's disease.J Dig Dis. 2019 May;20(5):243-247. doi: 10.1111/1751-2980.12717. Epub 2019 Apr 23.
• [271] A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population.Gastroenterology. 2013 Apr;144(4):781-8. doi: 10.1053/j.gastro.2012.12.021. Epub 2012 Dec 22.
• [272] Polymorphisms in Protein Tyrosine Phosphatase Non-receptor Type 2 and 22 (PTPN2/22) Are Linked to Hyper-Proliferative T-Cells and Susceptibility to Mycobacteria in Rheumatoid Arthritis.Front Cell Infect Microbiol. 2018 Jan 25;8:11. doi: 10.3389/fcimb.2018.00011. eCollection 2018.
• [273] High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.J Crohns Colitis. 2019 Sep 27;13(10):1343-1350. doi: 10.1093/ecco-jcc/jjz066.
• [274] Polymorphism in ICAM-1, PECAM-1, E-selectin, and L-selectin genes in Tunisian patients with inflammatory bowel disease.Eur J Gastroenterol Hepatol. 2009 Feb;21(2):167-75. doi: 10.1097/MEG.0b013e32830e6fc8.
• [275] ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.Gastroenterology. 2019 Mar;156(4):1098-1111. doi: 10.1053/j.gastro.2018.11.033. Epub 2018 Nov 16.
• [276] Association between OCTN1/2 gene polymorphisms (1672C-T, 207G-C) and susceptibility of Crohn's disease: a meta-analysis.Int J Colorectal Dis. 2012 Jan;27(1):11-9. doi: 10.1007/s00384-011-1265-x. Epub 2011 Jun 25.
• [277] Polymorphisms in the sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn disease.Am J Clin Nutr. 2014 Feb;99(2):378-83. doi: 10.3945/ajcn.113.068015. Epub 2013 Nov 27.
• [278] SLCO3A1, A novel crohn's disease-associated gene, regulates nf-B activity and associates with intestinal perforation.PLoS One. 2014 Jun 19;9(6):e100515. doi: 10.1371/journal.pone.0100515. eCollection 2014.
• [279] Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):466-473. doi: 10.1097/MPG.0000000000002458.
• [280] Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.J Biol Chem. 2017 Jun 30;292(26):10801-10812. doi: 10.1074/jbc.M116.771469. Epub 2017 May 10.
• [281] Succinate receptor mediates intestinal inflammation and fibrosis.Mucosal Immunol. 2019 Jan;12(1):178-187. doi: 10.1038/s41385-018-0087-3. Epub 2018 Oct 2.
• [282] Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome.Inflamm Bowel Dis. 2019 Mar 14;25(4):722-731. doi: 10.1093/ibd/izy359.
• [283] A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3).PLoS One. 2013 May 15;8(5):e64441. doi: 10.1371/journal.pone.0064441. Print 2013.
• [284] Erythrocyte transketolase deficiency in patients suffering from Crohn's disease.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8501-8505. doi: 10.26355/eurrev_201910_19163.
• [285] Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study.Clin Immunol. 2018 Dec;197:86-95. doi: 10.1016/j.clim.2018.09.001. Epub 2018 Sep 5.
• [286] MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.J Crohns Colitis. 2020 Mar 13;14(3):381-392. doi: 10.1093/ecco-jcc/jjz145.
• [287] Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn's disease.World J Gastroenterol. 2019 May 7;25(17):2071-2085. doi: 10.3748/wjg.v25.i17.2071.
• [288] Death Receptor 3 Signaling Controls the Balance between Regulatory and Effector Lymphocytes in SAMP1/YitFc Mice with Crohn's Disease-Like Ileitis.Front Immunol. 2018 Mar 1;9:362. doi: 10.3389/fimmu.2018.00362. eCollection 2018.
• [289] Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms.Med Sci Monit. 2016 Dec 7;22:4794-4802. doi: 10.12659/msm.902274.
• [290] Insight into the role of TSLP in inflammatory bowel diseases.Autoimmun Rev. 2017 Jan;16(1):55-63. doi: 10.1016/j.autrev.2016.09.014. Epub 2016 Oct 1.
• [291] The relationship between serum bilirubin and Crohn's disease.Inflamm Bowel Dis. 2014 Mar;20(3):481-7. doi: 10.1097/01.MIB.0000440817.84251.98.
• [292] Alterations in microRNA expression profiles in inflamed and noninflamed ascending colon mucosae of patients with active Crohn's disease.J Gastroenterol Hepatol. 2017 Oct;32(10):1706-1715. doi: 10.1111/jgh.13778.
• [293] Association of ZAP70 and PTPN6, but Not BANK1 or CLEC2D, with inflammatory bowel disease in the Tunisian population.Genet Test Mol Biomarkers. 2013 Apr;17(4):321-6. doi: 10.1089/gtmb.2012.0372. Epub 2013 Feb 13.
• [294] New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC.Inflamm Bowel Dis. 2009 Jul;15(7):971-84. doi: 10.1002/ibd.20893.
• [295] Analysis of a non-synonymous single nucleotide polymorphism of the human diamine oxidase gene (ref. SNP ID: rs1049793) in patients with Crohn's disease.Scand J Gastroenterol. 2009;44(10):1207-12. doi: 10.1080/00365520903171250.
• [296] Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies.Clin Exp Immunol. 2010 Nov;162(2):337-47. doi: 10.1111/j.1365-2249.2010.04248.x.
• [297] In vitro and in vivo silencing of plasmodial dhs and eIf-5a genes in a putative, non-canonical RNAi-related pathway.BMC Microbiol. 2012 Jun 13;12:107. doi: 10.1186/1471-2180-12-107.
• [298] Blood-based biomarkers can differentiate ulcerative colitis from Crohn's disease and noninflammatory diarrhea.Inflamm Bowel Dis. 2011 Aug;17(8):1719-25. doi: 10.1002/ibd.21574. Epub 2011 Jan 6.
• [299] Prioritizing candidate disease genes by network-based boosting of genome-wide association data.Genome Res. 2011 Jul;21(7):1109-21. doi: 10.1101/gr.118992.110. Epub 2011 May 2.
• [300] Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children.Am J Gastroenterol. 2008 Mar;103(3):615-20. doi: 10.1111/j.1572-0241.2007.01661.x. Epub 2007 Nov 28.
• [301] KCNN4 gene variant is associated with ileal Crohn's Disease in the Australian and New Zealand population.Am J Gastroenterol. 2010 Oct;105(10):2209-17. doi: 10.1038/ajg.2010.161. Epub 2010 Apr 20.
• [302] Genes involved in the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn's disease in children & young adults.PLoS One. 2010 Dec 20;5(12):e15672. doi: 10.1371/journal.pone.0015672.
• [303] Single nucleotide polymorphisms in C-type lectin genes, clustered in the IBD2 and IBD6 susceptibility loci, may play a role in the pathogenesis of inflammatory bowel diseases.Eur J Gastroenterol Hepatol. 2012 Aug;24(8):965-70. doi: 10.1097/MEG.0b013e328354f3d5.
• [304] Altered expression of CDX-2, PDX-1 and mucin core proteins in "Ulcer-associated cell lineage (UACL)" in Crohn's disease.J Mol Histol. 2008 Apr;39(2):161-8. doi: 10.1007/s10735-007-9149-7. Epub 2007 Oct 24.
• [305] Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease.Int J Colorectal Dis. 2009 Oct;24(10):1133-9. doi: 10.1007/s00384-009-0679-1. Epub 2009 Mar 10.
• [306] Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease.Gastroenterology. 2011 Jul;141(1):217-26, 226.e1-2. doi: 10.1053/j.gastro.2011.03.061. Epub 2011 Apr 7.
• [307] Real-time PCR quantification analysis of five mucosal transcripts in patients with Crohn's disease.Eur J Gastroenterol Hepatol. 2008 Apr;20(4):290-6. doi: 10.1097/MEG.0b013e3282f3557c.
• [308] Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2.Genes Immun. 2011 Dec;12(8):635-42. doi: 10.1038/gene.2011.41. Epub 2011 Jun 30.
• [309] SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects.PLoS One. 2019 Jan 31;14(1):e0211328. doi: 10.1371/journal.pone.0211328. eCollection 2019.
• [310] Single cell analysis of Crohn's disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties.J Gastroenterol. 2018 Sep;53(9):1035-1047. doi: 10.1007/s00535-018-1437-3. Epub 2018 Jan 27.
• [311] Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.Gastroenterology. 2016 Aug;151(2):278-287.e6. doi: 10.1053/j.gastro.2016.04.001. Epub 2016 Apr 8.
• [312] Galectin-4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function.FASEB J. 2016 Feb;30(2):544-54. doi: 10.1096/fj.15-272773. Epub 2015 Oct 19.
• [313] Significance of the genetic polymorphism of CYP2D6 and NAT2 in patients with inflammatory bowel diseases.Pharmacol Rep. 2014 Aug;66(4):686-90. doi: 10.1016/j.pharep.2014.04.002. Epub 2014 Apr 19.
• [314] Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.PLoS One. 2017 Dec 5;12(12):e0188925. doi: 10.1371/journal.pone.0188925. eCollection 2017.
• [315] Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene.World J Gastroenterol. 2005 Aug 21;11(31):4833-7. doi: 10.3748/wjg.v11.i31.4833.
• [316] Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum.Free Radic Biol Med. 2007 Sep 1;43(5):730-9. doi: 10.1016/j.freeradbiomed.2007.05.003. Epub 2007 May 10.
• [317] Immunosuppressed Patients with Crohn's Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database.J Gastrointest Surg. 2019 Jun;23(6):1188-1197. doi: 10.1007/s11605-019-04186-0. Epub 2019 Mar 18.
• [318] Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of Crohn's Disease.PLoS One. 2013 Aug 19;8(8):e72739. doi: 10.1371/journal.pone.0072739. eCollection 2013.
• [319] Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn's disease.Gastroenterology. 2014 Apr;146(4):929-31. doi: 10.1053/j.gastro.2013.12.034. Epub 2014 Jan 7.
• [320] The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A.J Immunol. 2012 Aug 15;189(4):1946-54. doi: 10.4049/jimmunol.1201064. Epub 2012 Jul 9.
• [321] Common polymorphisms in the microsomal epoxide hydrolase and N-acetyltransferase 2 genes in association with inflammatory bowel disease in the Danish population.Eur J Gastroenterol Hepatol. 2011 Mar;23(3):269-74. doi: 10.1097/MEG.0b013e3283438a44.
• [322] The role of fatty acid hydrolase gene variants in inflammatory bowel disease.Aliment Pharmacol Ther. 2009 Mar 1;29(5):542-51. doi: 10.1111/j.1365-2036.2008.03910.x. Epub 2008 Dec 2.
• [323] Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation.J Crohns Colitis. 2020 Jan 1;14(1):142-147. doi: 10.1093/ecco-jcc/jjz112.
• [324] Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.Dig Dis Sci. 2015 May;60(5):1236-46. doi: 10.1007/s10620-014-3478-7. Epub 2015 Feb 11.
• [325] Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.JAMA Neurol. 2016 Jun 1;73(6):691-7. doi: 10.1001/jamaneurol.2016.0150.
• [326] Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.J Gastroenterol. 2018 Sep;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Epub 2018 Jun 4.
• [327] Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease.Eur J Hum Genet. 2007 Mar;15(3):328-35. doi: 10.1038/sj.ejhg.5201756. Epub 2007 Jan 10.
• [328] Neutralization of IL-1 ameliorates Crohn's disease-like ileitis by functional alterations of the gut microbiome.Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26717-26726. doi: 10.1073/pnas.1915043116. Epub 2019 Dec 16.
• [329] A BACH2 Gene Variant Is Associated with Postoperative Recurrence of Crohn's Disease.J Am Coll Surg. 2018 May;226(5):902-908. doi: 10.1016/j.jamcollsurg.2018.01.052. Epub 2018 Feb 13.
• [330] A Genome-wide Association Study Identifying RAP1A as a Novel Susceptibility Gene for Crohn's Disease in Japanese Individuals.J Crohns Colitis. 2019 Apr 26;13(5):648-658. doi: 10.1093/ecco-jcc/jjy197.
• [331] Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn's disease.J Clin Pathol. 2005 Oct;58(10):1057-63. doi: 10.1136/jcp.2004.024828.
• [332] CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease.Gastroenterology. 2001 Aug;121(2):246-54. doi: 10.1053/gast.2001.27154.
• [333] Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.Inflamm Bowel Dis. 2011 Sep;17(9):1936-42. doi: 10.1002/ibd.21579. Epub 2010 Dec 10.
• [334] Treatment sequence network meta-analysis in Crohn's disease: a methodological case study.Curr Med Res Opin. 2019 May;35(5):733-756. doi: 10.1080/03007995.2019.1580094. Epub 2019 Mar 20.
• [335] Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.Clin Chem Lab Med. 2017 Aug 28;55(10):1574-1581. doi: 10.1515/cclm-2016-1120.
• [336] CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue.Eur J Immunol. 2004 Jul;34(7):1992-2000. doi: 10.1002/eji.200324807.
• [337] Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1.Inflamm Bowel Dis. 2004 May;10(3):173-81. doi: 10.1097/00054725-200405000-00001.
• [338] A specific gene-microbe interaction drives the development of Crohn's disease-like colitis in mice.Sci Immunol. 2019 Apr 19;4(34):eaaw4341. doi: 10.1126/sciimmunol.aaw4341.
• [339] Alpha-defensins (-Defs) in Crohn's disease: decrease of ileal -Def 5 via permanent methylation and increase in plasma -Def 1-3 concentrations offering biomarker utility.Clin Exp Immunol. 2018 Apr;192(1):120-128. doi: 10.1111/cei.13085. Epub 2018 Jan 10.
• [340] Gastric medullary carcinoma, a distinct entity associated with microsatellite instability-H, prominent intraepithelial lymphocytes and improved prognosis.Histopathology. 2004 Nov;45(5):485-92. doi: 10.1111/j.1365-2559.2004.01998.x.
• [341] Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro.World J Gastroenterol. 2005 Jul 14;11(26):4024-31. doi: 10.3748/wjg.v11.i26.4024.
• [342] Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.Blood. 1999 Mar 1;93(5):1684-96.
• [343] The mouse and human IGSF6 (DORA) genes map to the inflammatory bowel disease 1 locus and are embedded in an intron of a gene of unknown function.Immunogenetics. 2000 Nov;52(1-2):112-20. doi: 10.1007/s002510000259.
• [344] IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA.J Mol Med (Berl). 2017 Nov;95(11):1227-1236. doi: 10.1007/s00109-017-1585-6. Epub 2017 Sep 6.
• [345] Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.Int J Colorectal Dis. 2018 Jul;33(7):927-936. doi: 10.1007/s00384-018-3069-8. Epub 2018 May 11.
• [346] Innate Myeloid Cell Subset-Specific Gene Expression Patterns in the Human Colon are Altered in Crohn's Disease Patients.Digestion. 2019;99(3):194-204. doi: 10.1159/000490890. Epub 2018 Oct 19.
• [347] Allele frequency of inosine triphosphate pyrophosphatase (ITPA) and thiopurine-S-methyl transferase (TPMT) genes in the Tunisian population.Clin Res Hepatol Gastroenterol. 2012 Apr;36(2):178-84. doi: 10.1016/j.clinre.2011.12.001. Epub 2012 Jan 4.
• [348] Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis.Gut. 1995 Sep;37(3):380-5. doi: 10.1136/gut.37.3.380.
• [349] Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.Int Immunol. 2018 Apr 25;30(5):205-213. doi: 10.1093/intimm/dxy021.
• [350] Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.Nat Genet. 2008 Aug;40(8):955-62. doi: 10.1038/ng.175. Epub 2008 Jun 29.
• [351] NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8(+) T cell migration.Exp Mol Pathol. 2017 Aug;103(1):56-70. doi: 10.1016/j.yexmp.2017.06.010. Epub 2017 Jul 3.
• [352] Abnormalities in mucin gene expression in Crohn's disease.Inflamm Bowel Dis. 1999 Feb;5(1):24-32. doi: 10.1097/00054725-199902000-00004.
• [353] Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study.Eur J Hum Genet. 1999 Jul;7(5):567-73. doi: 10.1038/sj.ejhg.5200328.
• [354] The Selective Autophagy Receptor Optineurin in Crohn's Disease.Front Immunol. 2018 Apr 10;9:766. doi: 10.3389/fimmu.2018.00766. eCollection 2018.
• [355] Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Dec;23(12):2134-2141. doi: 10.1097/MIB.0000000000001252.
• [356] Association of SEEK1 polymorphisms in Crohn's disease.Hum Immunol. 2004 Jul;65(7):706-9. doi: 10.1016/j.humimm.2004.04.002.
• [357] IL18 polymorphism is associated with an increased risk of Crohn's disease.J Gastroenterol. 2002 Nov;37 Suppl 14:111-6. doi: 10.1007/BF03326428.
• [358] Defective paneth cell-mediated host defense in pediatric ileal Crohn's disease.Am J Gastroenterol. 2010 Feb;105(2):452-9. doi: 10.1038/ajg.2009.643. Epub 2009 Nov 10.
• [359] Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):788-794. doi: 10.26355/eurrev_201901_16893.
• [360] Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease.J Gastroenterol Hepatol. 2019 Apr;34(4):679-685. doi: 10.1111/jgh.14465. Epub 2018 Sep 27.
• [361] Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease.Clin Immunol. 2004 Sep;112(3):239-46. doi: 10.1016/j.clim.2004.04.009.
• [362] Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials.Inflamm Bowel Dis. 2020 Jan 1;26(1):125-131. doi: 10.1093/ibd/izz133.
• [363] The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.J Immunol. 2007 Sep 1;179(5):3109-18. doi: 10.4049/jimmunol.179.5.3109.
• [364] Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.J Proteome Res. 2007 Mar;6(3):1114-25. doi: 10.1021/pr060433m.
• [365] Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease.Gut. 2006 Aug;55(8):1114-23. doi: 10.1136/gut.2005.082107. Epub 2006 Feb 9.
• [366] Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease.J Mol Med (Berl). 2006 Dec;84(12):1055-66. doi: 10.1007/s00109-006-0100-2. Epub 2006 Oct 21.
• [367] Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes.Inflamm Bowel Dis. 2006 Jul;12(7):606-11. doi: 10.1097/01.ibd.0000225346.23765.6b.
• [368] A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses.Nat Immunol. 2007 May;8(5):497-503. doi: 10.1038/ni1459. Epub 2007 Apr 15.
• [369] Signature biomarkers in Crohn's disease: toward a molecular classification.Mucosal Immunol. 2008 Sep;1(5):399-411. doi: 10.1038/mi.2008.32. Epub 2008 Jul 2.
• [370] Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues.FEBS Lett. 2006 Oct 2;580(22):5344-50. doi: 10.1016/j.febslet.2006.08.083. Epub 2006 Sep 12.
• [371] An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29.Genes Immun. 2008 Mar;9(2):161-7. doi: 10.1038/sj.gene.6364460. Epub 2008 Jan 31.
• [372] Sequence variation, linkage disequilibrium and association with Crohn's disease on chromosome 5q31.Genes Immun. 2006 Jul;7(5):359-65. doi: 10.1038/sj.gene.6364307. Epub 2006 May 18.
• [373] Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease.Scand J Gastroenterol. 2008;43(11):1334-45. doi: 10.1080/00365520802200010.
• [374] Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn's Disease.J Crohns Colitis. 2019 Jul 25;13(7):894-904. doi: 10.1093/ecco-jcc/jjz012.
• [375] Identification of risk loci for Crohn's disease phenotypes using a genome-wide association study.Gastroenterology. 2015 Apr;148(4):794-805. doi: 10.1053/j.gastro.2014.12.030. Epub 2014 Dec 31.
• [376] Reduced Human -defensin 6 in Noninflamed Jejunal Tissue of Patients with Crohn's Disease.Inflamm Bowel Dis. 2016 May;22(5):1119-28. doi: 10.1097/MIB.0000000000000707.
• [377] Genetic Complexity of Crohn's Disease in Two Large Ashkenazi Jewish Families.Gastroenterology. 2016 Oct;151(4):698-709. doi: 10.1053/j.gastro.2016.06.040. Epub 2016 Jul 1.
• [378] Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease.Am J Gastroenterol. 2019 May;114(5):777-785. doi: 10.14309/ajg.0000000000000237.
• [379] Variable outcome in infantile-onset inflammatory bowel disease in an Asian cohort.World J Gastroenterol. 2016 Dec 28;22(48):10653-10662. doi: 10.3748/wjg.v22.i48.10653.
• [380] Association between genetic polymorphisms in interferon regulatory factor 5 (IRF5) gene and Malaysian patients with Crohn's disease.J Dig Dis. 2015 Apr;16(4):205-16. doi: 10.1111/1751-2980.12229.
• [381] Risk predisposition for Crohn disease: a "mnage trois" combining IRGM allele, miRNA and xenophagy.Autophagy. 2011 Jul;7(7):786-7. doi: 10.4161/auto.7.7.15595. Epub 2011 Jul 1.
• [382] Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome.PLoS One. 2019 Feb 28;14(2):e0213108. doi: 10.1371/journal.pone.0213108. eCollection 2019.
• [383] A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci.PLoS Genet. 2012;8(3):e1002559. doi: 10.1371/journal.pgen.1002559. Epub 2012 Mar 8.
• [384] Prevalence of Mycobacterium avium subspecies paratuberculosis IS 900 DNA in biopsy tissues from patients with Crohn's disease: histopathological and molecular comparison with Johne's disease in Fars province of Iran.BMC Infect Dis. 2019 Jan 7;19(1):23. doi: 10.1186/s12879-018-3619-2.
• [385] Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101606. doi: 10.1016/j.bpg.2019.03.002. Epub 2019 Mar 6.
• [386] Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients.Inflamm Bowel Dis. 2020 Feb 11;26(3):347-359. doi: 10.1093/ibd/izz242.
• [387] Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.PLoS One. 2017 Oct 13;12(10):e0185855. doi: 10.1371/journal.pone.0185855. eCollection 2017.
• [388] CARD4/NOD1 is not involved in inflammatory bowel disease.Gut. 2003 Jan;52(1):71-4. doi: 10.1136/gut.52.1.71.
• [389] Peptidoglycan Metabolite Photoaffinity Reporters Reveal Direct Binding to Intracellular Pattern Recognition Receptors and Arf GTPases.ACS Chem Biol. 2019 Mar 15;14(3):405-414. doi: 10.1021/acschembio.8b01038. Epub 2019 Feb 20.
• [390] Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.Inflamm Bowel Dis. 2012 Apr;18(4):603-12. doi: 10.1002/ibd.21851. Epub 2011 Sep 1.
• [391] Accounting for eXentricities: analysis of the X chromosome in GWAS reveals X-linked genes implicated in autoimmune diseases.PLoS One. 2014 Dec 5;9(12):e113684. doi: 10.1371/journal.pone.0113684. eCollection 2014.
• [392] Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2.PLoS One. 2013 Nov 5;8(11):e77773. doi: 10.1371/journal.pone.0077773. eCollection 2013.
• [393] Distinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1.J Immunol. 2019 Oct 1;203(7):1820-1829. doi: 10.4049/jimmunol.1800419. Epub 2019 Aug 26.
• [394] VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix.Genet Epidemiol. 2013 Sep;37(6):622-34. doi: 10.1002/gepi.21743. Epub 2013 Jul 8.
• [395] Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohn's disease.Abdom Radiol (NY). 2018 Dec;43(12):3207-3212. doi: 10.1007/s00261-018-1626-9.
• [396] Association of NOD2 and IL23R with inflammatory bowel disease in Puerto Rico.PLoS One. 2014 Sep 26;9(9):e108204. doi: 10.1371/journal.pone.0108204. eCollection 2014.
• [397] Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis.Dig Dis Sci. 2017 Sep;62(9):2348-2356. doi: 10.1007/s10620-017-4609-8. Epub 2017 May 18.
• [398] Effects of Recombinant Human Growth Hormone in Children with Crohn's Disease on the Muscle-Bone Unit: A Preliminary Study.Horm Res Paediatr. 2018;90(2):128-131. doi: 10.1159/000492398. Epub 2018 Aug 27.
• [399] Diversity of Gut Microbiota Affecting Serum Level of Undercarboxylated Osteocalcin in Patients with Crohn's Disease.Nutrients. 2019 Jul 8;11(7):1541. doi: 10.3390/nu11071541.
• [400] Novel Associations Between Major Histocompatibility Complex and Pediatric-onset Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):567-72. doi: 10.1097/MPG.0000000000000984.
• [401] Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493. doi: 10.1016/j.cgh.2018.04.060. Epub 2018 May 8.
• [402] Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies.Gastroenterology. 2013 Aug;145(2):339-47. doi: 10.1053/j.gastro.2013.04.040. Epub 2013 Apr 25.
• [403] Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease.J Inflamm (Lond). 2018 Jul 11;15:13. doi: 10.1186/s12950-018-0189-4. eCollection 2018.
• [404] Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.J Crohns Colitis. 2018 Feb 28;12(3):280-288. doi: 10.1093/ecco-jcc/jjx144.
• [405] CCDC88B is required for pathogenesis of inflammatory bowel disease.Nat Commun. 2017 Oct 13;8(1):932. doi: 10.1038/s41467-017-01381-y.
• [406] Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: a comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol.J Crohns Colitis. 2013 Sep;7(8):622-30. doi: 10.1016/j.crohns.2012.08.015. Epub 2012 Sep 24.
• [407] Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling.PLoS One. 2013 Aug 7;8(8):e70738. doi: 10.1371/journal.pone.0070738. eCollection 2013.
• [408] Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease.Clin Exp Immunol. 2019 Feb;195(2):251-264. doi: 10.1111/cei.13226. Epub 2018 Nov 28.
• [409] mTNF reverse signalling induced by TNF antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease.Gut. 2013 Mar;62(3):376-86. doi: 10.1136/gutjnl-2011-300384. Epub 2012 Apr 25.
• [410] Analysis of single nucleotide polymorphisms in the region of CLDN2-MORC4 in relation to inflammatory bowel disease.World J Gastroenterol. 2013 Aug 14;19(30):4935-43. doi: 10.3748/wjg.v19.i30.4935.
• [411] Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn's Disease Predominantly Caused by Genetic Predisposition.J Crohns Colitis. 2018 Nov 9;12(10):1200-1209. doi: 10.1093/ecco-jcc/jjy045.
• [412] Cytokine IL9 Triggers the Pathogenesis of Inflammatory Bowel Disease Through the miR21-CLDN8 Pathway.Inflamm Bowel Dis. 2018 Sep 15;24(10):2211-2223. doi: 10.1093/ibd/izy187.
• [413] MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.Cell Tissue Res. 2017 May;368(2):325-335. doi: 10.1007/s00441-017-2576-1. Epub 2017 Feb 11.
• [414] Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.Clin Gastroenterol Hepatol. 2019 Aug;17(9):1799-1806. doi: 10.1016/j.cgh.2018.09.008. Epub 2018 Sep 10.
• [415] Postoperative Interleukin-6 Predicts Intra-abdominal Septic Complications at an Early Stage After Elective Intestinal Operation for Crohn's Disease Patients.Inflamm Bowel Dis. 2018 Aug 16;24(9):1992-2000. doi: 10.1093/ibd/izy090.
• [416] Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients.Int J Oncol. 2007 Jul;31(1):97-102.
• [417] Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.
• [418] Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?.PLoS One. 2013;8(2):e56989. doi: 10.1371/journal.pone.0056989. Epub 2013 Feb 21.
• [419] Association of higher DEFB4 genomic copy number with Crohn's disease.Am J Gastroenterol. 2010 Feb;105(2):354-9. doi: 10.1038/ajg.2009.582. Epub 2009 Oct 6.
• [420] Exome sequencing identifies DLG1 as a novel gene for potential susceptibility to Crohn's disease in a Chinese family study.PLoS One. 2014 Jun 17;9(6):e99807. doi: 10.1371/journal.pone.0099807. eCollection 2014.
• [421] SALSA-A dance on a slippery floor with changing partners.Mol Immunol. 2017 Sep;89:100-110. doi: 10.1016/j.molimm.2017.05.029. Epub 2017 Jun 28.
• [422] ACG Clinical Guideline: Management of Crohn's Disease in Adults.Am J Gastroenterol. 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27.
• [423] Desmoglein 2, but not desmocollin 2, protects intestinal epithelia from injury.Mucosal Immunol. 2018 Nov;11(6):1630-1639. doi: 10.1038/s41385-018-0062-z. Epub 2018 Aug 16.
• [424] Villin-1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation.Gastroenterology. 2018 Apr;154(5):1405-1420.e2. doi: 10.1053/j.gastro.2017.12.016. Epub 2017 Dec 21.
• [425] Usefulness of confocal laser endomicroscopy for predicting postoperative recurrence in patients with Crohn's disease: apilot study.Gastrointest Endosc. 2019 Jul;90(1):151-157. doi: 10.1016/j.gie.2019.02.030. Epub 2019 Mar 5.
• [426] The distinct features of microbial 'dysbiosis' of Crohn's disease do not occur to the same extent in their unaffected, genetically-linked kindred.PLoS One. 2017 Feb 21;12(2):e0172605. doi: 10.1371/journal.pone.0172605. eCollection 2017.
• [427] Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease.Inflamm Bowel Dis. 2013 Jul;19(8):1662-70. doi: 10.1097/MIB.0b013e318281f275.
• [428] Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations.Gut. 2014 Jan;63(1):80-7. doi: 10.1136/gutjnl-2013-305193. Epub 2013 Jul 14.
• [429] FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease.Inflamm Bowel Dis. 2009 Sep;15(9):1351-7. doi: 10.1002/ibd.20895.
• [430] FKBP11 protects intestinal epithelial cells against inflammationinduced apoptosis via the JNKcaspase pathway in Crohn's disease.Mol Med Rep. 2018 Nov;18(5):4428-4438. doi: 10.3892/mmr.2018.9485. Epub 2018 Sep 14.
• [431] TAP gene transporter polymorphism in inflammatory bowel diseases.Scand J Gastroenterol. 1997 Oct;32(10):1022-7. doi: 10.3109/00365529709011219.
• [432] A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.Gut. 2013 Oct;62(10):1440-5. doi: 10.1136/gutjnl-2012-302865. Epub 2012 Aug 30.
• [433] Cryptic 13q34 and 4q35.2 Deletions in an Italian Family.Cytogenet Genome Res. 2015;147(1):24-30. doi: 10.1159/000442068. Epub 2015 Dec 9.
• [434] Association of FUT2 and ABO with Crohn's disease in Koreans.J Gastroenterol Hepatol. 2020 Jan;35(1):104-109. doi: 10.1111/jgh.14766. Epub 2019 Aug 7.
• [435] Identification of differentially expressed genes, associated functional terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by bioinformatics analysis.Exp Ther Med. 2019 Jul;18(1):278-288. doi: 10.3892/etm.2019.7541. Epub 2019 May 3.
• [436] Parallel Changes in Harvey-Bradshaw Index, TNF, and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease.Gastroenterol Res Pract. 2017;2017:1745918. doi: 10.1155/2017/1745918. Epub 2017 Oct 23.
• [437] Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.Turk J Gastroenterol. 2019 Jan;30(1):21-27. doi: 10.5152/tjg.2018.18135.
• [438] Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis.J Crohns Colitis. 2018 Nov 15;12(11):1348-1358. doi: 10.1093/ecco-jcc/jjy118.
• [439] Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3C as Contributors to Inflammatory Bowel Disease Susceptibility.Biomed Res Int. 2015;2015:834805. doi: 10.1155/2015/834805. Epub 2015 Sep 21.
• [440] Gene polymorphism linked to increased asthma and IBD risk alters gasdermin-B structure, a sulfatide and phosphoinositide binding protein.Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1128-E1137. doi: 10.1073/pnas.1616783114. Epub 2017 Feb 1.
• [441] Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-B pathway gene, HEATR3.Genes Immun. 2013 Jul-Aug;14(5):310-6. doi: 10.1038/gene.2013.19. Epub 2013 Apr 25.
• [442] Identifying candidate genes for discrimination of ulcerative colitis and Crohn's disease.Mol Biol Rep. 2014 Oct;41(10):6349-55. doi: 10.1007/s11033-014-3469-y. Epub 2014 Sep 3.
• [443] Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects.Hum Mol Genet. 2010 May 15;19(10):2059-67. doi: 10.1093/hmg/ddq078. Epub 2010 Feb 22.
• [444] Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease.Gut. 1998 Aug;43(2):210-5. doi: 10.1136/gut.43.2.210.
• [445] Haplotype synthesis analysis reveals functional variants underlying known genome-wide associated susceptibility loci.Bioinformatics. 2016 Jul 15;32(14):2136-42. doi: 10.1093/bioinformatics/btw125. Epub 2016 Mar 21.
• [446] Complex interaction between HNRNPD mutations and risk polymorphisms is associated with discordant Crohn's disease in monozygotic twins.Autoimmunity. 2017 Aug;50(5):275-276. doi: 10.1080/08916934.2017.1300883. Epub 2017 Mar 16.
• [447] Heat shock factor 2 levels are associated with the severity of ulcerative colitis.PLoS One. 2014 Feb 12;9(2):e88822. doi: 10.1371/journal.pone.0088822. eCollection 2014.
• [448] Heat shock protein family A member 6 combined with clinical characteristics for the differential diagnosis of intestinal Behet's disease.J Dig Dis. 2018 Jun;19(6):350-358. doi: 10.1111/1751-2980.12613.
• [449] Exome sequencing identifies novel compound heterozygous IFNA4 and IFNA10 mutations as a cause of impaired function in Crohn's disease patients.Sci Rep. 2015 May 22;5:10514. doi: 10.1038/srep10514.
• [450] IL-36 sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.Inflamm Bowel Dis. 2014 Nov;20(11):1891-901. doi: 10.1097/MIB.0000000000000198.
• [451] Interleukin-18 is increased only in a minority of patients with active Crohn's disease.Int J Colorectal Dis. 2007 Sep;22(9):1013-20. doi: 10.1007/s00384-007-0282-2. Epub 2007 Feb 21.
• [452] The novel interleukin-1 cytokine family members in inflammatory diseases.Curr Opin Rheumatol. 2017 Mar;29(2):208-213. doi: 10.1097/BOR.0000000000000361.
• [453] mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease.Cells. 2019 Aug 18;8(8):924. doi: 10.3390/cells8080924.
• [454] Interleukin-34 sustains inflammatory pathways in the gut.Clin Sci (Lond). 2015 Aug;129(3):271-80. doi: 10.1042/CS20150132.
• [455] Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis.Gastroenterology. 2018 Aug;155(2):303-306.e2. doi: 10.1053/j.gastro.2018.05.022. Epub 2018 Jul 5.
• [456] F-calprotectin and Blood Markers Correlate to Quality of Life in Pediatric Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):539-545. doi: 10.1097/MPG.0000000000001540.
• [457] Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific.Am J Gastroenterol. 2019 Jan;114(1):107-115. doi: 10.1038/s41395-018-0233-2.
• [458] Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II).Inflamm Bowel Dis. 2013 Feb;19(2):230-9. doi: 10.1002/ibd.23007.
• [459] Association of KIF21B genetic polymorphisms with ankylosing spondylitis in a Chinese Han population of Shandong Province.Clin Rheumatol. 2015 Oct;34(10):1729-36. doi: 10.1007/s10067-014-2761-5. Epub 2014 Aug 23.
• [460] An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.Cell Cycle. 2008 Aug 15;7(16):2570-83. doi: 10.4161/cc.7.16.6524. Epub 2008 Aug 30.
• [461] Critical role of Keratin 1 in maintaining epithelial barrier and correlation of its down-regulation with the progression of inflammatory bowel disease.Gene. 2017 Apr 15;608:13-19. doi: 10.1016/j.gene.2017.01.015. Epub 2017 Jan 20.
• [462] Genetic determinants associated with early age of diagnosis of IBD.Dis Colon Rectum. 2015 Mar;58(3):321-7. doi: 10.1097/DCR.0000000000000274.
• [463] Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.Inflamm Bowel Dis. 2012 Nov;18(11):2169-79. doi: 10.1002/ibd.22936. Epub 2012 Feb 28.
• [464] Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations.World J Gastroenterol. 2019 Apr 14;25(14):1753-1763. doi: 10.3748/wjg.v25.i14.1753.
• [465] Replication of genetic variation in the MYO9B gene in Crohn's disease.Hum Immunol. 2011 Jul;72(7):592-7. doi: 10.1016/j.humimm.2011.03.025. Epub 2011 Apr 12.
• [466] Microtubule-associated protein 1S-related autophagy inhibits apoptosis of intestinal epithelial cells via Wnt/-catenin signaling in Crohn's disease.Biochem Biophys Res Commun. 2017 Apr 8;485(3):635-642. doi: 10.1016/j.bbrc.2017.02.034. Epub 2017 Feb 7.
• [467] The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.Inflamm Bowel Dis. 2019 Aug 20;25(9):1474-1480. doi: 10.1093/ibd/izz005.
• [468] Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.Lancet Gastroenterol Hepatol. 2019 May;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3. Epub 2019 Feb 27.
• [469] Transcriptomic Analysis and High-dimensional Phenotypic Mapping of Mononuclear Phagocytes in Mesenteric Lymph Nodes Reveal Differences Between Ulcerative Colitis and Crohn's Disease.J Crohns Colitis. 2020 Mar 13;14(3):393-405. doi: 10.1093/ecco-jcc/jjz156.
• [470] Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries.Paediatr Int Child Health. 2019 Feb;39(1):48-58. doi: 10.1080/20469047.2019.1575056.
• [471] Mucosal genome-wide methylation changes in inflammatory bowel disease.Inflamm Bowel Dis. 2012 Nov;18(11):2128-37. doi: 10.1002/ibd.22942. Epub 2012 Mar 14.
• [472] Autoinflammatory disease with focus on NOD2-associated disease in the era of genomic medicine.Autoimmunity. 2019 Mar;52(2):48-56. doi: 10.1080/08916934.2019.1613382. Epub 2019 May 13.
• [473] DNA Methylation of miR-122 Aggravates Oxidative Stress in Colitis Targeting SELENBP1 Partially by p65NF-B Signaling.Oxid Med Cell Longev. 2019 Mar 24;2019:5294105. doi: 10.1155/2019/5294105. eCollection 2019.
• [474] Eosinophil associated genes in the inflammatory bowel disease 4 region: correlation to inflammatory bowel disease revealed.World J Gastroenterol. 2012 Nov 28;18(44):6409-19; discussion p. 6417-8. doi: 10.3748/wjg.v18.i44.6409.
• [475] Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis.Cell Death Dis. 2018 Jun 7;9(6):691. doi: 10.1038/s41419-018-0734-3.
• [476] MIS416 Enhances Therapeutic Functions of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Against Experimental Colitis by Modulating Systemic Immune Milieu.Front Immunol. 2018 May 28;9:1078. doi: 10.3389/fimmu.2018.01078. eCollection 2018.
• [477] Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress.Autophagy. 2013 Dec;9(12):2046-55. doi: 10.4161/auto.26337. Epub 2013 Nov 14.
• [478] The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis.Mucosal Immunol. 2017 Jul;10(4):983-995. doi: 10.1038/mi.2016.102. Epub 2016 Nov 30.
• [479] A meta-analysis of the relationship between MYO9B gene polymorphisms and susceptibility to Crohn's disease and ulcerative colitis.Hum Immunol. 2016 Oct;77(10):990-996. doi: 10.1016/j.humimm.2016.07.008. Epub 2016 Jul 18.
• [480] CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors.J Immunol. 2019 Jan 1;202(1):171-182. doi: 10.4049/jimmunol.1701153. Epub 2018 Nov 30.
• [481] The use of selected neutrophil protein plasma concentrations in the diagnosis of Crohn's disease and ulcerative colitis - a preliminary report.Postepy Hig Med Dosw (Online). 2017 Apr 6;71(0):243-253. doi: 10.5604/01.3001.0010.3810.
• [482] Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients.J Crohns Colitis. 2014 Oct;8(10):1208-16. doi: 10.1016/j.crohns.2014.02.009. Epub 2014 Mar 15.
• [483] Gastrointestinal Tract Pathology in a BALB/c Niemann-Pick Disease Type C1 Null Mouse Model.Dig Dis Sci. 2018 Apr;63(4):870-880. doi: 10.1007/s10620-018-4914-x. Epub 2018 Jan 22.
• [484] Crohn's disease loci are common targets of protozoa-driven selection.Mol Biol Evol. 2013 May;30(5):1077-87. doi: 10.1093/molbev/mst020. Epub 2013 Feb 6.
• [485] Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.J Gastroenterol. 2018 Feb;53(2):172-180. doi: 10.1007/s00535-017-1416-0. Epub 2017 Nov 30.
• [486] Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.Gut. 2012 Apr;61(4):528-34. doi: 10.1136/gut.2011.240978. Epub 2011 Jun 27.
• [487] Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behet's disease.Clin Transl Gastroenterol. 2018 Feb 15;9(2):e133. doi: 10.1038/ctg.2018.1.
• [488] Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.Leuk Lymphoma. 2019 Jul;60(7):1782-1788. doi: 10.1080/10428194.2018.1542152. Epub 2018 Nov 20.
• [489] Expression and localization of pannexin-1 hemichannels in human colon in health and disease.Neurogastroenterol Motil. 2013 Jun;25(6):e395-405. doi: 10.1111/nmo.12130. Epub 2013 Apr 17.
• [490] Pannexin-2 is expressed in the human colon with extensive localization in the enteric nervous system.Neurogastroenterol Motil. 2015 May;27(5):672-83. doi: 10.1111/nmo.12541. Epub 2015 Mar 14.
• [491] Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis.Neurogastroenterol Motil. 2011 Oct;23(10):935-e398. doi: 10.1111/j.1365-2982.2011.01749.x. Epub 2011 Jul 14.
• [492] Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel Disease.PLoS One. 2013 Jun 19;8(6):e67393. doi: 10.1371/journal.pone.0067393. Print 2013.
• [493] IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes.Int J Mol Med. 2011 Mar;27(3):469-77. doi: 10.3892/ijmm.2010.591. Epub 2010 Dec 27.
• [494] A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
• [495] PRDM5 promotes the apoptosis of epithelial cells induced by IFN- during Crohn's disease.Pathol Res Pract. 2017 Jun;213(6):666-673. doi: 10.1016/j.prp.2016.12.004. Epub 2016 Dec 5.
• [496] Molecular cloning reveals nearly half of patients with Crohn's disease have an antibody to peroxiredoxin 6-like protein.J Gastroenterol Hepatol. 2012 Aug;27(8):1388-94. doi: 10.1111/j.1440-1746.2012.07147.x.
• [497] Decreased Expression of Prox1 Is Associated With Postoperative Recurrence in Crohn's Disease.J Crohns Colitis. 2018 Nov 9;12(10):1210-1218. doi: 10.1093/ecco-jcc/jjy091.
• [498] Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease.Protein Cell. 2017 Sep;8(9):686-695. doi: 10.1007/s13238-017-0413-7. Epub 2017 May 18.
• [499] Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with Crohn disease in French patients.Dig Dis Sci. 2010 Jun;55(6):1681-8. doi: 10.1007/s10620-009-0929-7.
• [500] Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.Scand J Gastroenterol. 2017 May;52(5):564-569. doi: 10.1080/00365521.2017.1284893. Epub 2017 Feb 13.
• [501] NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2.Gut. 2012 Jul;61(7):1028-35. doi: 10.1136/gutjnl-2011-300078. Epub 2011 Sep 7.
• [502] Neutrophil GM-CSF signaling in inflammatory bowel disease patients is influenced by non-coding genetic variants.Sci Rep. 2019 Jun 24;9(1):9168. doi: 10.1038/s41598-019-45701-2.
• [503] Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.Scand J Gastroenterol. 2019 Oct;54(10):1237-1244. doi: 10.1080/00365521.2019.1670251. Epub 2019 Oct 2.
• [504] Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity inCrohn's Disease.Gastroenterology. 2017 Jul;153(1):219-232. doi: 10.1053/j.gastro.2017.04.002. Epub 2017 Apr 9.
• [505] R-Spondins Are Expressed by the Intestinal Stroma and are Differentially Regulated during Citrobacter rodentium- and DSS-Induced Colitis in Mice.PLoS One. 2016 Apr 5;11(4):e0152859. doi: 10.1371/journal.pone.0152859. eCollection 2016.
• [506] Preliminary exploration of the potential of spliceosome-associated protein 130 for predicting disease severity in Crohn's disease.Ann N Y Acad Sci. 2020 Feb;1462(1):128-138. doi: 10.1111/nyas.14240. Epub 2019 Oct 3.
• [507] Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand.Nutrients. 2012 Sep;4(9):1247-59. doi: 10.3390/nu4091247. Epub 2012 Sep 7.
• [508] Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.Scand J Gastroenterol. 2016;51(6):684-91. doi: 10.3109/00365521.2015.1133698. Epub 2016 Jan 14.
• [509] T-cell activation Rho GTPase-activating protein expression varies with inflammation location and severity in Crohn's disease.J Surg Res. 2014 Aug;190(2):457-64. doi: 10.1016/j.jss.2014.01.019. Epub 2014 Jan 17.
• [510] TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease.Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G487-98. doi: 10.1152/ajpgi.00347.2013. Epub 2014 Jul 3.
• [511] An Analysis of Transcobalamin II Gene Polymorphisms and Serum Levels of Homocysteine, Folate and Vitamin B12 in Chinese Patients with Crohn's Disease.Dig Dis. 2017;35(5):463-471. doi: 10.1159/000471848. Epub 2017 May 5.
• [512] Utility of in vitro interferon- release assay in differential diagnosis between intestinal tuberculosis and Crohn's disease.J Dig Dis. 2013 Feb;14(2):68-75. doi: 10.1111/1751-2980.12017.
• [513] Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population.Hum Immunol. 2012 Apr;73(4):416-20. doi: 10.1016/j.humimm.2012.01.015. Epub 2012 Feb 2.
• [514] TNFAIP6 is a potential biomarker of disease activity in inflammatory bowel disease.Biomark Med. 2016 May;10(5):473-83. doi: 10.2217/bmm.16.9. Epub 2016 Apr 18.
• [515] Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.Int J Med Sci. 2013;10(2):156-63. doi: 10.7150/ijms.5457. Epub 2013 Jan 3.
• [516] IB kinase phosphorylation of TRAF4 downregulates innate immune signaling.Mol Cell Biol. 2012 Jul;32(13):2479-89. doi: 10.1128/MCB.00106-12. Epub 2012 Apr 30.
• [517] Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease.J Gastroenterol Hepatol. 2019 Dec;34(12):2118-2125. doi: 10.1111/jgh.14696. Epub 2019 Jun 18.
• [518] Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.Gastroenterology. 2016 May;150(5):1196-1207. doi: 10.1053/j.gastro.2016.01.031. Epub 2016 Feb 4.
• [519] Gut Microbial Signatures Underline Complicated Crohn's Disease but Vary Between Cohorts; An In Silico Approach.Inflamm Bowel Dis. 2019 Jan 10;25(2):217-225. doi: 10.1093/ibd/izy328.
• [520] Granulomas in Crohn's disease: are newly discovered genetic variants involved?.J Crohns Colitis. 2010 Oct;4(4):438-43. doi: 10.1016/j.crohns.2010.02.006. Epub 2010 Apr 22.
• [521] Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease.Hum Mol Genet. 2010 Sep 1;19(17):3468-76. doi: 10.1093/hmg/ddq248. Epub 2010 Jun 22.
• [522] A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility.Nat Genet. 2010 Jun;42(6):515-9. doi: 10.1038/ng.583. Epub 2010 May 9.
• [523] Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study.Circ Cardiovasc Genet. 2009 Apr;2(2):134-41. doi: 10.1161/CIRCGENETICS.108.825273. Epub 2009 Feb 12.
• [524] NOD2 status and human ileal gene expression.Inflamm Bowel Dis. 2010 Oct;16(10):1649-57. doi: 10.1002/ibd.21208.
• [525] Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study.Ann Hum Genet. 2010 Nov;74(6):489-97. doi: 10.1111/j.1469-1809.2010.00606.x. Epub 2010 Sep 15.
• [526] Association of celiac disease genes with inflammatory bowel disease in Finnish and Swedish patients.Genes Immun. 2012 Sep;13(6):474-80. doi: 10.1038/gene.2012.21. Epub 2012 May 17.
• [527] Enterovirulent E. coli in inflammatory and noninflammatory bowel diseases.Folia Microbiol (Praha). 2009;54(1):81-6. doi: 10.1007/s12223-009-0012-y. Epub 2009 Mar 29.
• [528] TLE1 modifies the effects of NOD2 in the pathogenesis of Crohn's disease.Gastroenterology. 2011 Sep;141(3):972-981.e1-2. doi: 10.1053/j.gastro.2011.05.043. Epub 2011 May 27.
• [529] Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC.J Immunol. 2011 Apr 1;186(7):4027-38. doi: 10.4049/jimmunol.1000085. Epub 2011 Feb 18.
• [530] Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease.Inflamm Bowel Dis. 2009 Jun;15(6):883-9. doi: 10.1002/ibd.20855.
• [531] Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort.Inflamm Bowel Dis. 2009 Sep;15(9):1358-67. doi: 10.1002/ibd.20892.
• [532] Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes.J Rheumatol. 2010 Feb;37(2):401-9. doi: 10.3899/jrheum.090456. Epub 2009 Dec 23.
• [533] Caspase-8 regulates TNF--induced epithelial necroptosis and terminal ileitis.Nature. 2011 Sep 14;477(7364):335-9. doi: 10.1038/nature10400.
• [534] NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity.J Immunol. 2011 Apr 15;186(8):4649-55. doi: 10.4049/jimmunol.1003888. Epub 2011 Mar 7.
• [535] The genetics of NOD-like receptors in Crohn's disease.Tissue Antigens. 2010 Jul;76(1):48-56. doi: 10.1111/j.1399-0039.2010.01470.x. Epub 2010 Apr 6.
• [536] Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease.Dig Liver Dis. 2010 Aug;42(8):544-8. doi: 10.1016/j.dld.2009.12.005. Epub 2010 Jan 12.
• [537] Association of the RAVER2 gene with increased susceptibility for ulcerative colitis.Hum Immunol. 2012 Jul;73(7):732-5. doi: 10.1016/j.humimm.2012.04.018. Epub 2012 May 2.
• [538] Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease.J Cancer Res Clin Oncol. 2010 Jun;136(6):795-802. doi: 10.1007/s00432-009-0719-9. Epub 2009 Nov 19.
• [539] Influence of smoking on colonic gene expression profile in Crohn's disease.PLoS One. 2009 Jul 15;4(7):e6210. doi: 10.1371/journal.pone.0006210.
• [540] Loss of Smad5 leads to the disassembly of the apical junctional complex and increased susceptibility to experimental colitis.Am J Physiol Gastrointest Liver Physiol. 2011 Apr;300(4):G586-97. doi: 10.1152/ajpgi.00041.2010. Epub 2011 Jan 6.
• [541] Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1?.Neurogastroenterol Motil. 2011 May;23(5):475-83, e179-80. doi: 10.1111/j.1365-2982.2011.01685.x. Epub 2011 Feb 22.
• [542] Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease.Inflamm Bowel Dis. 2008 Apr;14(4):500-7. doi: 10.1002/ibd.20365.